Management of adult patients with ascites due to cirrho

Hepatology 49, 2087-2107

DOI: 10.1002/hep.22853

Citation Report

#	Article	IF	CITATIONS
1	Low dose albumin for the prevention of renal impairment following large volume paracentesis in cirrhosis Pakistan Journal of Medical Sciences, 1969, 31, 592-6.	0.6	1
2	The safety and feasibility of large volume paracentesis performed by an experienced nurse practitioner. Annals of Hepatology, 2009, 8, 359-363.	1.5	22
3	The management of patients awaiting liver transplantation. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 648-659.	17.8	7
4	The management of cirrhotic ascites. Hepatology, 2009, 50, 1320-1320.	7.3	1
5	Role of cholesterol determination in ascitic fluid analysis. Hepatology, 2009, 50, 1320-1320.	7.3	9
6	Spontaneous bacterial peritonitis: A severe complication ofliver cirrhosis. World Journal of Gastroenterology, 2009, 15, 5505.	3.3	66
9	Balancing volume resuscitation and ascites management in cirrhosis. Current Opinion in Anaesthesiology, 2010, 23, 151-158.	2.0	21
10	Characterisation of bacteria in ascitesâ€"reporting the potential of culture-independent, molecular analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 533-541.	2.9	28
11	Hepatitis C and End-stage Liver Disease. Current Hepatitis Reports, 2010, 9, 243-252.	0.3	0
12	Targeting Diuretic Use for Malignant Ascitesâ€"Two Case Reports Highlighting the Value of the Serum-Ascites Albumin Gradient in a Palliative Setting. Journal of Pain and Symptom Management, 2010, 39, e7-e9.	1.2	3
13	Critical care management of patients before liver transplantation. Transplantation Reviews, 2010, 24, 190-206.	2.9	18
14	C-reactive protein as a specific marker of infection in cirrhotic patients. Liver International, 2010, 30, 487-488.	3.9	O
15	Current Treatment Strategies: Diuretics. Frontiers of Gastrointestinal Research, 2010, , 11-22.	0.1	0
16	Pathogenesis and management of alcoholic liver cirrhosis: a review. Hepatic Medicine: Evidence and Research, 2010, 3, 1.	2.5	10
17	Spontaneous Bacterial Peritonitis – Prophylaxis and Treatment. Frontiers of Gastrointestinal Research, 2010, , 65-82.	0.1	0
18	Malnutrition and nutrition support in patients with liver disease. Frontline Gastroenterology, 2010, 1, 105-111.	1.8	33
19	Evaluation of the new body fluid mode on the Sysmex XE-5000 for counting leukocytes and erythrocytes in cerebrospinal fluid and other body fluids. Clinical Chemistry and Laboratory Medicine, 2010, 48, 665-675.	2.3	64
20	Paracentesis. Frontiers of Gastrointestinal Research, 2011, , 23-31.	0.1	1

#	Article	IF	CITATIONS
22	Management of End-Stage Liver Disease in Chronic Hepatitis B. Clinics in Liver Disease, 2010, 14, 477-493.	2.1	3
23	An Explicit Quality Indicator Set for Measurement of Quality of Care in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2010, 8, 709-717.	4.4	109
24	Antibiotic Prophylaxis for Prevention of Spontaneous Bacterial Peritonitis in Patients Without Gastrointestinal Bleeding. Annals of Pharmacotherapy, 2010, 44, 1946-1954.	1.9	11
25	Management of Ascites. Critical Care Nursing Clinics of North America, 2010, 22, 309-314.	0.8	1
26	Prolonging Survival in Patients With Cirrhosis: Old Drugs With New Indications. Gastroenterology, 2010, 139, 1813-1815.e1.	1.3	22
27	Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives. Journal of Hepatology, 2010, 53, 1135-1145.	3.7	97
29	Cirrhotic Patients Are at Risk for Health Care–Associated Bacterial Infections. Clinical Gastroenterology and Hepatology, 2010, 8, 979-985.e1.	4.4	274
30	Diuretic agents for ascites: joining forces from the start?. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 310-311.	17.8	1
31	Care of the Liver Transplant Candidate. Clinics in Liver Disease, 2011, 15, 779-806.	2.1	1
32	Immune Dysfunction and Infections in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2011, 9, 727-738.	4.4	299
34	Antimicrobial Prophylaxis in Adults. Mayo Clinic Proceedings, 2011, 86, 686-701.	3.0	163
35	Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation?. Clinical Gastroenterology and Hepatology, 2011, 9, 931-935.	4.4	3
36	The management of patients awaiting liver transplantation. Indian Journal of Transplantation, 2011, 5, 66-71.	0.1	0
37	Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis. Gastroenterology, 2011, 140, 488-496.e4.	1.3	311
38	Therapie des zirrhotischen Aszites. DoctorConsult - the Journal Wissen Fur Klinik Und Praxis, 2011, 2, e192-e196.	0.0	0
39	Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Digestive and Liver Disease, 2011, 43, 881-6.	0.9	54
40	Management of hepatorenal syndrome in patients with cirrhosis. Nature Reviews Nephrology, 2011, 7, 517-526.	9.6	58
41	Management of patients with cirrhosis awaiting liver transplantation. Gut, 2011, 60, 412-421.	12.1	64

#	ARTICLE	IF	CITATIONS
43	Review of Use of Drugs for Conditions Not Included in Product Characteristics. Farmacia Hospitalaria (English Edition), 2011, 35, 264-277.	0.0	2
44	The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: A multicentric study. European Journal of Internal Medicine, 2011, 22, 587-590.	2.2	30
45	Medical management of ascites. Expert Opinion on Pharmacotherapy, 2011, 12, 1269-1283.	1.8	9
46	Integrating Palliative Care with Chronic Liver Disease Care. Journal of Palliative Care, 2011, 27, 20-27.	1.0	25
47	Management of liver cirrhosis between primary care and specialists. World Journal of Gastroenterology, 2011, 17, 2273.	3.3	45
48	Diagnosis and therapy of ascites in liver cirrhosis. World Journal of Gastroenterology, 2011, 17, 1237.	3.3	80
49	Critical care management of patients with end-stage liver disease. Critical Care Medicine, 2011, 39, 1157-1166.	0.9	27
52	Bacterial DNA in the diagnosis of spontaneous bacterial peritonitis. Alimentary Pharmacology and Therapeutics, 2011, 33, 275-284.	3.7	40
53	Revisi $\tilde{A}^3$ n sobre el uso de medicamentos en condiciones no incluidas en su ficha t $\tilde{A}$ ©cnica. Farmacia Hospitalaria, 2011, 35, 264-277.	0.6	14
54	Testing Beneficial Therapy in Human Cirrhosis Using Animal Models of Cirrhosis. Digestive Diseases and Sciences, 2011, 56, 929-930.	2.3	0
55	Potential Preventability of Spontaneous Bacterial Peritonitis. Digestive Diseases and Sciences, 2011, 56, 2728-2734.	2.3	10
56	Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. Journal of Gastroenterology, 2011, 46, 78-85.	5.1	139
57	Prevalence and risk factors for unsuspected spontaneous ascitic fluid infection in cirrhotics undergoing therapeutic paracentesis in an outpatient clinic. Indian Journal of Gastroenterology, 2011, 30, 221-224.	1.4	13
59	Validity of diagnostic codes and liverâ€related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiology and Drug Safety, 2011, 20, 689-699.	1.9	123
60	Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites. Hepatology, 2011, 53, 1068-1069.	7.3	4
61	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. Hepatology, 2011, 54, 91-100.	7.3	188
62	Autopsy findings of a patient with rapidly progressive massive ascites caused by alcoholic cirrhosis. Legal Medicine, 2011, 13, 148-150.	1.3	2
64	COMPLICATIONS OF ALCOHOLIC LIVER DISEASE AND DIAGNOSTIC MARKERS. Acta Medica Medianae, 2011, , 55-61.	0.1	1

#	ARTICLE	lF	CITATIONS
65	Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites. Clinical Science, 2011, 121, 509-521.	4.3	9
66	Intestinal inflammation—key to complications in cirrhosis?. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 665-667.	17.8	0
67	Ascites in Adult Patients With Cyanotic Congenital Heart Disease. World Journal for Pediatric & Disease.	0.8	2
68	A Primer on Detecting Cirrhosis and Caring for These Patients without Causing Harm. International Journal of Hepatology, 2011, 2011, 1-8.	1.1	18
69	Ascites and spontaneous bacterial peritonitis. , 2012, , 159-172.		0
70	Management of Refractory Ascites. American Journal of Therapeutics, 2012, 19, 121-132.	0.9	31
71	Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut, 2012, 61, 108-116.	12.1	121
72	Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease: Figure 1:. Cmaj, 2012, 184, 1365-1371.	2.0	72
73	Assessment of the Quality of Evidence Underlying International Guidelines in Liver Disease. American Journal of Gastroenterology, 2012, 107, 1276-1282.	0.4	17
74	The Pharmacokinetics and Pharmacodynamics of Tolvaptan in Patients with Liver Cirrhosis with Insufficient Response to Conventional Diuretics: a Multicentre, Double-blind, Parallel-group, Phase III Study. Journal of International Medical Research, 2012, 40, 2381-2393.	1.0	32
75	Liver injury in the elderly due to fluoroquinolones: Should these drugs be avoided?. Cmaj, 2012, 184, 1555-1556.	2.0	4
76	Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. Therapeutic Advances in Gastroenterology, 2012, 5, 275-283.	3.2	19
77	Infectious Complications of Acute and Chronic Liver Disease. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 80-95.	2.1	86
79	The Role of Rifaximin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis. Journal of Clinical Gastroenterology, 2012, 46, 709-715.	2.2	83
81	Continuous Furosemide Infusion in the Management of Ascites. Journal of Investigative Medicine, 2012, 60, 671-675.	1.6	5
84	Ascitis y sÃndrome hepatorrenal. Medicine, 2012, 11, 644-651.	0.0	0
86	Management of bacterial infections in cirrhosis. Journal of Hepatology, 2012, 56, S1-S12.	3.7	296
87	Shortness of Breath in the Patient with Chronic Liver Disease. Clinics in Liver Disease, 2012, 16, 321-329.	2.1	10

#	ARTICLE	IF	CITATIONS
89	Predictors of Posthepatectomy Ascites with or without Previous Portal Vein Embolization. Digestive Surgery, 2012, 29, 468-474.	1.2	10
90	New therapeutic paradigm for patients with cirrhosis. Hepatology, 2012, 56, 1983-1992.	7.3	108
91	Characteristics of Ascites in Patients With Pregnancy-Specific Liver Diseases. Clinical Gastroenterology and Hepatology, 2012, 10, 559-562.	4.4	7
92	Evaluation of hospital complications and costs associated with using ultrasound guidance during abdominal paracentesis procedures. Journal of Medical Economics, 2012, 15, 1-7.	2.1	45
93	Care of the Cirrhotic Patient. Infectious Disease Clinics of North America, 2012, 26, 979-994.	5.1	5
94	Surgical Clearance for the Patient with Chronic Liver Disease. Clinics in Liver Disease, 2012, 16, 421-433.	2.1	7
95	Mycobacterial peritonitis: difference between non-tuberculous mycobacteria and Mycobacterium tuberculosis. Clinical Microbiology and Infection, 2012, 18, 246-252.	6.0	21
96	Development of a new in situ hybridization method for the detection of global bacterial DNA to provide early evidence of a bacterial infection in spontaneous bacterial peritonitis. Journal of Hepatology, 2012, 56, 85-94.	3.7	23
97	Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. Journal of Hepatology, 2012, 56, 825-832.	3.7	134
98	Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. Journal of Hepatology, 2012, 57, 759-765.	3.7	179
99	Congenital heart disease and the liver. Hepatology, 2012, 56, 1160-1169.	7.3	174
101	Ascites. Clinics in Liver Disease, 2012, 16, 285-299.	2.1	38
102	Acute Decompensation in Chronic Liver Failure. , 2012, , 335-340.		0
103	Emergence of spontaneous bacterial peritonitis due to enterococci – risk factors and outcome in a 12â€year retrospective study. Alimentary Pharmacology and Therapeutics, 2012, 35, 1199-1208.	3.7	57
105	The Dietary Approaches to Stop Hypertension (DASH) Eating Pattern in Special Populations. Current Hypertension Reports, 2012, 14, 388-396.	3.5	47
106	The Quality of Care Provided to Patients With Cirrhosis and Ascites in the Department of Veterans Affairs. Gastroenterology, 2012, 143, 70-77.	1.3	133
107	Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure. Journal of Critical Care, 2012, 27, 744.e7-744.e15.	2.2	37
108	Role of Nurse Practitioners in the Management of Cirrhotic Patients. Journal for Nurse Practitioners, 2012, 8, 816-821.	0.8	9

#	Article	IF	CITATIONS
109	Intravenous albumin for the prevention of contrast-induced nephropathy in patients with liver cirrhosis and chronic kidney disease undergoing contrast-enhanced CT. Kidney Research and Clinical Practice, 2012, 31, 106-111.	2.2	9
110	Management of ascites in cirrhosis and portal hypertension. , 2012, , 1121-1128.e2.		0
111	Infectious Disease Emergencies. Medical Clinics of North America, 2012, 96, 1033-1066.	2.5	0
112	Role of Albumin Treatment in Patients With Spontaneous Bacterial Peritonitis. Clinical Gastroenterology and Hepatology, 2012, 10, 309-315.	4.4	73
114	Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS). CardioVascular and Interventional Radiology, 2012, 35, 1295-1300.	2.0	69
115	Simulation-Based Education with Mastery Learning Improves Paracentesis Skills. Journal of Graduate Medical Education, 2012, 4, 23-27.	1.3	121
116	Kidneys in chronic liver diseases. World Journal of Gastroenterology, 2012, 18, 3035.	3.3	66
117	Review of Laboratory and Diagnostic Tests. , 2012, , 86-122.		1
118	Revision and update on clinical practice guideline for liver cirrhosis. The Korean Journal of Hepatology, 2012, 18, 1.	1.5	120
119	Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World Journal of Hepatology, 2012, 4, 158.	2.0	50
120	Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials. Hepatology, 2012, 55, 1172-1181.	7.3	285
121	Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study. Hepatology, 2012, 55, 1551-1561.	7.3	498
122	Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology, 2012, 55, 1931-1941.	7.3	177
123	Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut, 2012, 61, 297-310.	12.1	303
124	Risk stratification of spontaneous bacterial peritonitis in cirrhosis with ascites based on classification and regression tree analysis. Molecular Biology Reports, 2012, 39, 6161-6169.	2.3	16
126	Can 24â€h urine sodium excretion be replaced by spot urine sodium/potassium in patients with decompensated cirrhosis?. Liver International, 2012, 32, 172-173.	3.9	8
127	Management of ascites in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 11-20.	2.8	68
128	Hepatorenal Syndrome: A Severe, but Treatable, Cause of Kidney Failure in Cirrhosis. American Journal of Kidney Diseases, 2012, 59, 874-885.	1.9	58

#	Article	IF	CITATIONS
129	Different patterns of decompensation in patients with alcoholic vs. nonâ€alcoholic liver cirrhosis. Alimentary Pharmacology and Therapeutics, 2012, 35, 1443-1450.	3.7	27
130	Hepatorenal Syndrome: Are We Missing Some Prognostic Factors?. Digestive Diseases and Sciences, 2012, 57, 210-214.	2.3	16
132	AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations. Hepatology, 2013, 58, 2142-2152.	7.3	54
133	How to improve care in outpatients with cirrhosis and ascites: A new model of care coordination by consultant hepatologists. Journal of Hepatology, 2013, 59, 257-264.	3.7	146
134	The new epidemiology of nosocomial bacterial infections in cirrhosis: therapeutical implications. Hepatology International, 2013, 7, 72-79.	4.2	18
135	Paradigms in the management of hepatic hydrothorax: past, present, and future. Hepatology International, 2013, 7, 80-87.	4.2	5
136	Body fluid analysis: Clinical utility and applicability of published studies to guide interpretation of today's laboratory testing in serous fluids. Critical Reviews in Clinical Laboratory Sciences, 2013, 50, 107-124.	6.1	38
137	Albumin Infusion Improves Outcomes of Patients With Spontaneous Bacterial Peritonitis: A Meta-analysis of Randomized Trials. Clinical Gastroenterology and Hepatology, 2013, 11, 123-130.e1.	4.4	171
138	Nutrition Assessment and Management in Advanced Liver Disease. Nutrition in Clinical Practice, 2013, 28, 15-29.	2.4	124
139	Automated low flow pump system for the treatment of refractory ascites: A multi-center safety and efficacy study. Journal of Hepatology, 2013, 58, 922-927.	3.7	114
141	New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection. Gastroenterology, 2013, 145, 1280-1288.e1.	1.3	221
142	A French national survey on the use of antibiotic prophylaxis in cirrhotic patients. Liver International, 2013, 33, 389-397.	3.9	12
143	Improving quality of care in patients with cirrhosis. Clinical Liver Disease, 2013, 2, 123-124.	2.1	5
144	Polymorphonuclear counts in ascitic fluid and microorganisms producing spontaneous bacterial peritonitis: an under-recognized relationship. Scandinavian Journal of Gastroenterology, 2013, 48, 1213-1221.	1.5	9
145	Determinants of long-term outcome in severe alcoholic hepatitis. Alimentary Pharmacology and Therapeutics, 2013, 38, 584-595.	3.7	103
146	Diuretics aggravate zinc deficiency in patients with liver cirrhosis by increasing zinc excretion in urine. Hepatology Research, 2013, 43, 365-373.	3.4	33
147	Association Between Ratio of Sodium to Potassium in Random Urine Samples and Renal Dysfunction and Mortality in Patients With Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology, 2013, 11, 862-867.	4.4	11
148	Pre-liver transplant protocols in dentistry. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 115, 426-430.	0.4	17

#	ARTICLE	IF	CITATIONS
150	Assessment of neutrophil gelatinase-associated lipocalin and lactate dehydrogenase in peritoneal fluids for the screening of bacterial peritonitis. Clinica Chimica Acta, 2013, 418, 59-62.	1.1	17
151	Hemorrhagic ascites. Clinical presentation and outcomes in patients with cirrhosis. Journal of Hepatology, 2013, 58, 1113-1118.	3.7	29
152	83-Year-Old Man With Abdominal Swelling and Lower Extremity Edema. Mayo Clinic Proceedings, 2013, 88, e115-e118.	3.0	0
153	Clinical Outcomes after Bedside and Interventional Radiology Paracentesis Procedures. American Journal of Medicine, 2013, 126, 349-356.	1.5	77
154	Update in Critical Care for the Nephrologist: Transfusion in Nonhemorrhaging Critically Ill Patients. Advances in Chronic Kidney Disease, 2013, 20, 30-38.	1.4	6
155	Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nature Reviews Cancer, 2013, 13, 273-282.	28.4	439
156	Management of ascites in patients with liver cirrhosis: Recent evidence and controversies. Journal of the Chinese Medical Association, 2013, 76, 123-130.	1.4	26
157	Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology, 2013, 58, 1836-1846.	7.3	327
158	Patient Knowledge About Disease Self-Management in Cirrhosis. American Journal of Gastroenterology, 2013, 108, 302-305.	0.4	81
159	Spontaneous ascitic fluid infection in liver cirrhosis: bacteriological profile and response to antibiotic therapy. Indian Journal of Gastroenterology, 2013, 32, 297-301.	1.4	11
160	Multidisciplinary Management of Patients With Cirrhosis: A Need for Care Coordination. Clinical Gastroenterology and Hepatology, 2013, 11, 217-223.	4.4	80
161	Hepatitis and Cirrhosis. , 2013, , 343-351.		0
162	Management of patients with complications of cirrhosis. Nurse Practitioner, 2013, 38, 14-22.	0.3	8
164	PTU-088â€Variation in Practice of Management of Spontaneous Bacterial Peritonitis (SBP). Gut, 2013, 62, A81.3-A82.	12.1	0
165	Short-Term Pretransplant Renal Replacement Therapy and Renal Nonrecovery after Liver Transplantation Alone. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1135-1142.	4.5	74
166	Trans-jugular intrahepatic porto-systemic shunt placement for refractory ascites: a â€real-world' UK health economic evaluation: Table 1. Frontline Gastroenterology, 2013, 4, 182-186.	1.8	2
167	Albumin Reduces Paracentesis-Induced Circulatory Dysfunction and Reduces Death and Renal Impairment among Patients with Cirrhosis and Infection: A Systematic Review and Meta-Analysis. BioMed Research International, 2013, 2013, 1-8.	1.9	33
168	CD4+ T-Cell Function and the Risk for Developing Spontaneous Bacterial Peritonitis in Patients With Cirrhosis. Journal of Clinical Gastroenterology, 2013, 47, 807-813.	2.2	3

#	Article	IF	Citations
169	Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. Journal of International Medical Research, 2013, 41, 835-847.	1.0	48
170	Prevention of paracentesis-induced circulatory dysfunction. Egyptian Liver Journal, 2013, 3, 118-125.	0.6	5
171	Re: Nonsteroidal Anti-inflammatory Drug Use, Chronic Liver Disease, and Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2013, 105, 667-667.	6.3	1
172	Treatment of refractory ascites. Clinical Liver Disease, 2013, 2, 140-142.	2.1	4
173	Sequential therapy with entecavir and <scp>PEGâ€INF</scp> in patients affected by chronic hepatitis <scp>B</scp> and high levels of <scp>HBVâ€DNA</scp> with nonâ€ <scp>D</scp> genotypes. Journal of Viral Hepatitis, 2013, 20, e11-9.	2.0	34
174	A fatal complication of ultrasoundâ€guided abdominal paracentesis. Journal of Clinical Ultrasound, 2013, 41, 457-460.	0.8	8
175	Bacterial infections in cirrhosis: A growing problem with significant implications. Clinical Liver Disease, 2013, 2, 102-105.	2.1	29
176	The 22/11 Risk Prediction Model: A Validated Model for Predicting 30-Day Mortality in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. American Journal of Gastroenterology, 2013, 108, 1473-1479.	0.4	40
177	Current Concepts in the Diagnosis and Classification of Renal Dysfunction in Cirrhosis. American Journal of Nephrology, 2013, 38, 345-354.	3.1	27
178	Making Paracentesis Safer. Chest, 2013, 143, 1136-1139.	0.8	29
179	Trauma center level impacts survival for cirrhotic trauma patients. Journal of Trauma and Acute Care Surgery, 2013, 74, 1133-1137.	2.1	9
180	Cirrhotic ascites review: Pathophysiology, diagnosis and management. World Journal of Hepatology, 2013, 5, 251.	2.0	90
181	Liver disease. , 0, , 196-202.		0
182	Diagnosis and management of bacterial infections in decompensated cirrhosis. World Journal of Hepatology, 2013, 5, 16.	2.0	47
183	Diagnosis and Management of Delayed Hemoperitoneum Following Therapeutic Paracentesis. Baylor University Medical Center Proceedings, 2013, 26, 185-186.	0.5	7
184	NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis. ISRN Hepatology, 2013, 2013, 1-7.	0.9	1
185	What Is the Clinical Course of Advanced Liver Disease and What Symptoms Are Associated With It?., 2013, , 300-307.		1
186	Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Annals of Hepatology, 2013, 12, 431-439.	1.5	44

#	Article	IF	CITATIONS
187	Cirrhosis and its complications: Evidence based treatment. World Journal of Gastroenterology, 2014, 20, 5442.	3.3	171
188	Third-Generation Cephalosporin-Resistant Spontaneous Bacterial Peritonitis: A single-Centre Experience and Summary of Existing Studies. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 83-88.	1.9	36
189	TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: An updated meta-analysis. World Journal of Gastroenterology, 2014, 20, 2704.	3.3	124
190	Multi-resistant bacteria in spontaneous bacterial peritonitis: A new step in management?. World Journal of Gastroenterology, 2014, 20, 14079.	3.3	38
191	New determinants of prognosis in bacterial infections in cirrhosis. World Journal of Gastroenterology, 2014, 20, 7252.	3.3	21
192	Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites. Annals of Hepatology, 2014, 13, 357-363.	1.5	37
193	Akin criteria as a predictor of mortality in cirrhotic patients after spontaneous bacterial peritonitis. Annals of Hepatology, 2014, 13, 390-395.	1.5	13
194	The impact of bacterial infections on survival of patients with decompensated cirrhosis. Annals of Hepatology, 2014, 13, 7-19.	1.5	28
196	Macrophages from Patients with Cirrhotic Ascites Showed Function Alteration of Host Defense Receptor. Journal of Clinical and Experimental Hepatology, 2014, 4, 279-286.	0.9	1
197	Chylous Ascites: Evaluation and Management. ISRN Hepatology, 2014, 2014, 1-10.	0.9	109
198	Diagnosis of Spontaneous Bacterial Peritonitis and an <i>In Situ</i> Hybridization Approach to Detect an "Unidentified―Pathogen. International Journal of Hepatology, 2014, 2014, 1-7.	1.1	22
199	Non-typhoidal salmonella: an unusual cause of spontaneous bacterial peritonitis in decompensated cirrhosis. Gastroenterology Report, 2014, 2, 242-244.	1.3	5
200	Percutaneous Portosystemic Shunts: TIPS and Beyond. Seminars in Interventional Radiology, 2014, 31, 227-234.	0.8	11
201	Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites: A diagnostic accuracy study. Hepatology, 2014, 59, 1043-1051.	7.3	42
202	Novel additional indication of tolvaptan: Can tolvaptan provide a beneficial therapeutic option in cirrhotic patients with ascites?. Hepatology Research, 2014, 44, 70-72.	3.4	1
203	Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change?. Internal Medicine Journal, 2014, 44, 865-872.	0.8	47
204	Monitoring and Care. , 2014, , 478-493.		0
205	A Risk Scoring System to Predict In-hospital Mortality in Patients With Cirrhosis Presenting With Upper Gastrointestinal Bleeding. Journal of Clinical Gastroenterology, 2014, 48, 712-720.	2.2	48

#	Article	IF	CITATIONS
206	Management of refractory hepatic hydrothorax. Current Opinion in Pulmonary Medicine, 2014, 20, 352-357.	2.6	44
207	Outpatient Interventions for Hepatology Patients With Fluid Retention. Gastroenterology Nursing, 2014, 37, 236-244.	0.4	5
209	Co-Management Between Hospitalist and Hepatologist Improves the Quality of Care of Inpatients With Chronic Liver Disease. Journal of Clinical Gastroenterology, 2014, 48, e30-e36.	2.2	36
210	Managing alcoholic liver disease. Nursing, 2014, 44, 30-40.	0.3	10
211	Predictors of Negative Intraoperative Findings at Emergent Laparotomy in Patients with Cirrhosis. Journal of Gastrointestinal Surgery, 2014, 18, 1777-1783.	1.7	1
212	Specialties performing paracentesis procedures at university hospitals: Implications for training and certification. Journal of Hospital Medicine, 2014, 9, 162-168.	1.4	19
213	Hemorrhagic Complications of Paracentesis: A Systematic Review of the Literature. Gastroenterology Research and Practice, 2014, 2014, 1-6.	1.5	45
214	Ascites and spontaneous bacterial peritonitis: Recommendations from two United States centers. Saudi Journal of Gastroenterology, 2014, 20, 279.	1.1	17
215	Toward reliable and rapid bedside diagnosis of spontaneous bacterial peritonitis in cirrhotic patients. Egyptian Liver Journal, 2014, 4, 50-56.	0.6	0
216	Cost Savings of Performing Paracentesis Procedures at the Bedside After Simulation-based Education. Simulation in Healthcare, 2014, 9, 312-318.	1.2	48
217	HIV/Hepatitis C Virus-Coinfected Patients and Cirrhosis: How to Diagnose It and What to Do Next?. Clinical Infectious Diseases, 2014, 58, 840-847.	5.8	6
218	Spontaneous Bacterial Peritonitis. Hospital Medicine Clinics, 2014, 3, e350-e361.	0.2	0
219	Resultados de una encuesta sobre la prÃ;ctica clÃnica habitual en el empleo de albúmina en UCI. Medicina Intensiva, 2014, 38, 403-412.	0.7	4
220	Changing Options for Prevention and Treatment of Infections in Cirrhosis. Current Treatment Options in Gastroenterology, 2014, 12, 256-267.	0.8	10
221	Laboratory diagnostics of spontaneous bacterial peritonitis. Clinica Chimica Acta, 2014, 430, 164-170.	1.1	21
222	A rapid, low-cost quantitative diagnostic method for hepatitis C virus infection using capillary zone electrophoresis. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 439-452.	2.9	4
223	Impact of preoperative uncontrollable hepatic hydrothorax and massive ascites in adult liver transplantation. Surgery Today, 2014, 44, 2293-2299.	1.5	12
224	Effects of paracentesis on hemodynamic parameters and respiratory function in critically ill patients. BMC Gastroenterology, 2014, 14, 18.	2.0	12

#	Article	IF	CITATIONS
225	Hyponatraemia and cirrhosis. Gastroenterology Report, 2014, 2, 21-26.	1.3	26
226	Systemic diseases and biotherapies: Understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine, 2014, 81, 478-484.	1.6	23
228	Paracentesis Is Associated With Reduced Mortality in Patients Hospitalized With Cirrhosis and Ascites. Clinical Gastroenterology and Hepatology, 2014, 12, 496-503.e1.	4.4	77
229	Liver cirrhosis. Lancet, The, 2014, 383, 1749-1761.	13.7	1,425
231	Evaluation of the <scp>S</scp> ysmex <scp>XT</scp> â€4000 <i>i</i> i for the automated body fluid analysis. International Journal of Laboratory Hematology, 2014, 36, 114-123.	1.3	10
233	Pathophysiology, diagnosis, and management of hepatic encephalopathy. Inflammopharmacology, 2014, 22, 319-326.	3.9	10
234	What to do when leak happens. Liver International, 2014, 34, 1287-1287.	3.9	1
235	Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized, Controlled Trial. Gastroenterology, 2014, 147, 1327-1337.e3.	1.3	287
236	Results of a survey on albumin use in clinical practice in intensive care units. Medicina Intensiva (English Edition), 2014, 38, 403-412.	0.2	0
237	MELD Score and Albumin Replacement Are Related to Higher Costs During Management of Patients With Refractory Ascites. Transplantation Proceedings, 2014, 46, 1760-1763.	0.6	4
238	Randomized, controlled pilot study comparing large-volume paracentesis using wall suction and traditional glass vacuum bottle methods. Therapeutic Advances in Gastroenterology, 2014, 7, 184-192.	3.2	4
240	Common GI Drug Interactions in the Elderly. Current Treatment Options in Gastroenterology, 2014, 12, 292-309.	0.8	6
241	Advanced Disease, Diuretic Use, and Marital Status Predict Hospital Admissions in an Ambulatory Cirrhosis Cohort. Digestive Diseases and Sciences, 2014, 59, 174-182.	2.3	18
242	Central venous pressure catheter for large-volume paracentesis in refractory ascites. Indian Journal of Gastroenterology, 2014, 33, 310-315.	1.4	5
243	Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study. BMC Infectious Diseases, 2014, 14, 287.	2.9	54
244	Use of a transjugular intrahepatic portosystemic shunt combined with autologous bone marrow cell infusion in patients with decompensated liver cirrhosis: an exploratory study. Cytotherapy, 2014, 16, 1575-1583.	0.7	2
245	Procalcitonin and macrophage inflammatory protein-1 beta (MIP- $1\hat{l}^2$ ) in serum and peritoneal fluid of patients with decompensated cirrhosis and spontaneous bacterial peritonitis. Advances in Medical Sciences, 2014, 59, 52-56.	2.1	46
246	Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients. Clinical and Translational Gastroenterology, 2014, 5, e56.	2.5	40

#	ARTICLE	IF	CITATIONS
247	Avaliação da natriurese no doente cirrótico: determinação pontual Na+/K+na urina ou doseamento de sódio na urina de 24 horas?. GE Jornal Português De Gastrenterologia, 2014, 21, 7-8.	0.0	0
248	A multicenter prospective study of infections related morbidity and mortality in cirrhosis of liver. Indian Journal of Gastroenterology, 2014, 33, 336-342.	1.4	27
249	Comparative study of spot urine Na/K ratio and 24-hour urine sodium in natriuresis evaluation of cirrhotic patients with ascites. GE Jornal Portuguós De Gastrenterologia, 2014, 21, 15-20.	0.0	5
250	Hepatic Hydrothorax. Clinics in Liver Disease, 2014, 18, 439-449.	2.1	31
251	Antibiotic prophylaxis for pre–liver transplant patients: where is the evidence?. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 117, 259-260.	0.4	2
253	Letter: underutilisation of albumin infusion in high-risk spontaneous bacterial peritonitis. Alimentary Pharmacology and Therapeutics, 2015, 42, 241-242.	3.7	2
254	Bleeding Rate for Ultrasoundâ€Guided Paracentesis in Thrombocytopenic Patients. Journal of Ultrasound in Medicine, 2015, 34, 1833-1838.	1.7	23
255	Indwelling peritoneal catheters in patients with cirrhosis and refractory ascites. Internal Medicine Journal, 2015, 45, 1026-1031.	0.8	19
256	Key Controversies in Colloid and Crystalloid Fluid Utilization. Hospital Pharmacy, 2015, 50, 446-453.	1.0	8
257	Serum Hypoalbuminemia Predicts Late Mortality on the Liver Transplant Waiting List. Transplantation, 2015, 99, 158-163.	1.0	19
258	Poor outcomes after hepatectomy in patients with ascites infected by methicillinâ€resistant staphylococci. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 166-176.	2.6	6
259	Spontaneous fungal peritonitis: a devastating complication of cirrhosis. Mycoses, 2015, 58, 387-393.	4.0	24
260	Risk Factors for Developing Hyponatremia During Terlipressin Treatment. Journal of Clinical Gastroenterology, 2015, 49, 607-612.	2.2	27
261	Diagnostic Accuracy of Serum Procalcitonin for Spontaneous Bacterial Peritonitis Due to End-stage Liver Disease. Medicine (United States), 2015, 94, e2077.	1.0	22
262	Interleukinâ€1 receptor antagonist correlates with hepatic venous pressure gradient and predicts occurrence of overall complications and bacterial infections in patients with cirrhosis. Hepatology Research, 2015, 45, 294-304.	3.4	3
263	Comparison between automated and microscopic analysis in body fluids cytology. International Journal of Laboratory Hematology, 2015, 37, e16-e18.	1.3	10
264	Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology, 2015, 21, 4975.	3.3	65
265	In-hospital mortality risk factors in patients with ascites due to cirrhosis. Revista Da Associa $\tilde{A}$ § $\tilde{A}$ £o M $\tilde{A}$ ©dica Brasileira, 2015, 61, 35-39.	0.7	8

#	Article	IF	CITATIONS
266	Management options in decompensated cirrhosis. Hepatic Medicine: Evidence and Research, 2015, 7, 43.	2.5	13
267	Multiresistant bacterial infections in liver cirrhosis: Clinical impact and new empirical antibiotic treatment policies. World Journal of Hepatology, 2015, 7, 916.	2.0	28
268	Case Report of Granulicatella adiacensas a Cause of Bacterascites. Case Reports in Infectious Diseases, 2015, 2015, 1-5.	0.5	2
269	The performance of prognostic models as predictors of mortality in patients with acute decompensation of cirrhosis. Annals of Hepatology, 2015, 14, 83-92.	1.5	10
270	Mean platelet volume as a novel predictor of systemic inflammatory response in cirrhotic patients with culture-negative neutrocytic ascites. World Journal of Hepatology, 2015, 7, 1001.	2.0	4
274	Toward the Effective Co-management of Patients with Cirrhosis by Primary Care Providers and Specialists. Digestive Diseases and Sciences, 2015, 60, 2576-2578.	2.3	2
275	Ascites. British Journal of Hospital Medicine (London, England: 2005), 2015, 76, C23-C27.	0.5	3
276	Diagnosing bacterial peritonitis made easy by use of leukocyte esterase dipsticks. International Journal of Critical Illness and Injury Science, 2015, 5, 32.	0.6	6
277	The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials. BMC Gastroenterology, 2015, 15, 65.	2.0	44
278	Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options. Seminars in Interventional Radiology, 2015, 32, 445-454.	0.8	24
279	Safety of Ascitic Paracentesis in Patients with Budd-Chiari Syndrome on Oral Anticoagulation and Elevated International Normalized Ratio. Journal of Clinical and Experimental Hepatology, 2015, 5, 310-313.	0.9	7
280	Isotopic analysis of Cu in blood serum by multi-collector ICP-mass spectrometry: a new approach for the diagnosis and prognosis of liver cirrhosis?. Metallomics, 2015, 7, 491-498.	2.4	88
281	Singleâ€centre validation of the <scp>EASL</scp> â€ <scp>CLIF</scp> Consortium definition of acuteâ€onâ€chronic liver failure and <scp>CLIF</scp> â€ <scp>SOFA</scp> for prediction of mortality in cirrhosis. Liver International, 2015, 35, 1516-1523.	3.9	74
282	Body Fluid Cell Counts by Automated Methods. Clinics in Laboratory Medicine, 2015, 35, 93-103.	1.4	37
283	Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts. CardioVascular and Interventional Radiology, 2015, 38, 913-921.	2.0	17
284	Critical Care Management in Cirrhosis. Current Hepatology Reports, 2015, 14, 60-68.	0.9	0
285	Understanding the Complexities of Cirrhosis. Clinical Therapeutics, 2015, 37, 1822-1836.	2.5	37
286	Successful treatment of occult hepatitis B virus infection related membranous nephropathy after entecavir therapy. Acta Clinica Belgica, 2015, 70, 223-225.	1.2	5

#	Article	IF	CITATIONS
287	Application of next-generation sequencing to study ascitic microbiome in cirrhotic patients with or without spontaneous bacterial peritonitis. Journal of Microbiology, Immunology and Infection, 2015, 48, 504-509.	3.1	18
288	Decreasing Mortality Among Patients Hospitalized With Cirrhosis in the United States From 2002 Through 2010. Gastroenterology, 2015, 148, 967-977.e2.	1.3	116
289	Management of hepatorenal syndrome. World Journal of Nephrology, 2015, 4, 277.	2.0	25
290	Treatment to Improve Acute Kidney Injury in Cirrhosis. Current Treatment Options in Gastroenterology, 2015, 13, 235-248.	0.8	4
291	Management of cirrhotic ascites. Therapeutic Advances in Chronic Disease, 2015, 6, 124-137.	2.5	55
292	Review article: spontaneous bacterial peritonitis – bacteriology, diagnosis, treatment, risk factors and prevention. Alimentary Pharmacology and Therapeutics, 2015, 41, 1116-1131.	3.7	144
293	Influence of splenorenal shunt on long-term outcomes in cirrhosis. Scandinavian Journal of Gastroenterology, 2015, 50, 593-600.	1.5	15
294	Assessment of renal functions in patients of chronic liver disease. Renal Failure, 2015, 37, 1457-1463.	2.1	3
296	Management of ascites in children. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1281-1292.	3.0	25
297	Traditional Iranian medicine: The use of the Canon of medicine by Avicenna to treat ascites. European Journal of Integrative Medicine, 2015, 7, 674-678.	1.7	2
298	Patient experience of non-malignant ascites and its treatment: a qualitative study. International Journal of Palliative Nursing, 2015, 21, 372-379.	0.5	14
299	Tratamiento de la hepatopat $ ilde{A}$ a alcoh $ ilde{A}$ 3lica. Nursing (Ed Espa $ ilde{A}$ $\pm$ ola), 2015, 32, 18-27.	0.0	0
300	Two Unusual but Treatable Causes of Refractory Ascites After Liver Transplantation. CardioVascular and Interventional Radiology, 2015, 38, 1663-1669.	2.0	1
301	Type 2 diabetes: A risk factor for liver mortality and complications in hepatitis <scp>B</scp> cirrhosis patients. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 591-599.	2.8	60
302	Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a realâ€life crossâ€sectional study. Liver International, 2015, 35, 1508-1515.	3.9	63
303	Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in <scp>S</scp> outh <scp>A</scp> uckland, <scp>N</scp> ew <scp>Z</scp> ealand. Internal Medicine Journal, 2015, 45, 160-169.	0.8	27
304	Acute kidney injury and hepatorenal syndrome in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 236-243.	2.8	42
305	Surveillance for Infectious Complications in Pediatric Acute Liver Failure - A Prospective Study. Indian Journal of Pediatrics, 2015, 82, 260-266.	0.8	3

#	Article	IF	CITATIONS
306	Portal hypertension: pathophysiology, diagnosis and management. Internal Medicine Journal, 2015, 45, 16-26.	0.8	76
307	A new flow cytometric method for differential cell counting in ascitic fluid. Cytometry Part B - Clinical Cytometry, 2016, 90, 506-511.	1.5	18
308	PREVALENCE OF BACTERIAL RESISTANCE IN HOSPITALIZED CIRRHOTIC PATIENTS IN SOUTHERN BRAZIL: A NEW CHALLENGE. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2016, 58, 36.	1.1	11
309	Bacterial infections in cirrhosis: A critical review and practical guidance. World Journal of Hepatology, 2016, 8, 307.	2.0	146
310	Predictors of fifty days in-hospital mortality in decompensated cirrhosis patients with spontaneous bacterial peritonitis. World Journal of Hepatology, 2016, 8, 566.	2.0	27
311	Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis. World Journal of Hepatology, 2016, 8, 739.	2.0	10
312	The Palliative Management of Refractory Cirrhotic Ascites Using the PleurX <	1.9	24
313	Intestinal permeability in a patient with liver cirrhosis. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1729-1748.	2.0	33
314	Fulminant Ulcerative Colitis Complicated by Treatment-Refractory Bacteremia. Baylor University Medical Center Proceedings, 2016, 29, 407-408.	0.5	1
315	Fungal Peritonitis: Underestimated Disease in Critically III Patients with Liver Cirrhosis and Spontaneous Peritonitis. PLoS ONE, 2016, 11, e0158389.	2.5	31
316	Selfâ€expanding metal stents for acute refractory esophageal variceal bleeding: A systematic review and metaâ€analysis. Digestive Endoscopy, 2016, 28, 539-547.	2.3	47
317	Predictive Factors of Spontaneous Bacterial Peritonitis Caused by Gram-Positive Bacteria in Patients With Cirrhosis. Medicine (United States), 2016, 95, e3489.	1.0	18
318	Solid organ transplant patients: are there opportunities for antimicrobial stewardship?. Clinical Transplantation, 2016, 30, 659-668.	1.6	45
319	Elevated creatinine in a patient with cirrhosis. Clinical Liver Disease, 2016, 7, 48-52.	2.1	3
320	The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. Hepatology, 2016, 63, 1299-1309.	7.3	186
321	The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Review of Quality of Life in Cancer Care, 2016, 1, 231-238.	0.6	12
322	Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection. Arthritis Care and Research, 2016, 68, 738-743.	3.4	48
323	Thrombelastographyâ€guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology, 2016, 63, 566-573.	7.3	336

#	ARTICLE	IF	CITATIONS
324	The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome. European Journal of Gastroenterology and Hepatology, 2016, 28, e10-e18.	1.6	70
325	Ascitis: diagn $ ilde{A}^3$ stico diferencial y tratamiento. Medicine, 2016, 12, 673-682.	0.0	1
326	Manejo de la ascitis refractaria. Medicine, 2016, 12, 707-710.	0.0	0
327	Enhanced <scp>LL</scp> â€37 expression following vitamin D supplementation in patients with cirrhosis and spontaneous bacterial peritonitis. Liver International, 2016, 36, 68-75.	3.9	14
328	Combination of a Flipped Classroom Format and a Virtual Patient Case to Enhance Active Learning in a Required Therapeutics Course. American Journal of Pharmaceutical Education, 2016, 80, 175.	2.1	37
330	Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis?. Expert Review of Gastroenterology and Hepatology, 2016, 11, 1-2.	3.0	14
331	Idiopathic chylous ascites simulating acute appendicitis: A case report and literature review. International Journal of Surgery Case Reports, 2016, 29, 189-192.	0.6	3
332	Nutrition, fluid, and electrolytes in chronic liver disease. Clinical Liver Disease, 2016, 7, 18-20.	2.1	12
333	Ascitis, insuficiencia renal aguda y encefalopatÃa hepática. Medicine, 2016, 12, 617-626.	0.0	0
334	Malnutrition is related to a higher frequency of serious complications in patients with cirrhosis. Revista Médica Del Hospital General De México, 2016, 79, 11-16.	0.0	6
335	Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. Digestive Diseases and Sciences, 2016, 61, 3084-3092.	2.3	23
336	Behavior and clinical impact of ascites after living donor liver transplantation: risk factors associated with massive ascites. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 688-696.	2.6	15
337	Nutrition Interventions for Chronic Liver Diseases and Nonalcoholic Fatty Liver Disease. Medical Clinics of North America, 2016, 100, 1303-1327.	2.5	8
338	Hepatorenal Syndrome: Diagnosis and Treatment – newsreel –. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2016, 54, 143-150.	0.6	2
339	Predictive model of mortality in patients with spontaneous bacterial peritonitis. Alimentary Pharmacology and Therapeutics, 2016, 44, 629-637.	3.7	19
340	Albumin to Reduce Mortality in Cirrhotic Patients with Acute Kidney Injury., 2016,, 133-141.		0
341	Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and metaâ€analysis. Journal of Digestive Diseases, 2016, 17, 11-19.	1.5	15
342	Intraâ€abdominal Hypertension: An Important Consideration for Diuretic Resistance in Acute Decompensated Heart Failure. Clinical Cardiology, 2016, 39, 37-40.	1.8	14

#	Article	IF	Citations
343	Letter: the emergence of multi-drug resistant spontaneous bacterial peritonitis: a new challenge for the hepatologist? Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 945-946.	3.7	0
344	Management of uninfected and infected ascites in cirrhosis. Liver International, 2016, 36, 109-115.	3.9	43
345	Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis. Clinical Drug Investigation, 2016, 36, 829-835.	2.2	17
346	Prevention of the Paracentesis-Induced Circulatory Dysfunction (PICD) in Cirrhosis: Is the SPA Treatment Worthwhile?. Digestive Diseases and Sciences, 2016, 61, 2773-2775.	2.3	2
347	Clinical characteristics and outcome of cirrhotic patients with high protein concentrations in ascites. European Journal of Gastroenterology and Hepatology, 2016, 28, 1268-1274.	1.6	3
348	Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare. Journal of Pain and Symptom Management, 2016, 52, 412-419.e1.	1.2	25
349	Wall suction-assisted image-guided therapeutic paracentesis: a safe and less expensive alternative to evacuated bottles. Abdominal Radiology, 2016, 41, 1333-1337.	2.1	4
350	Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis. European Journal of Gastroenterology and Hepatology, 2016, 28, 777-785.	1.6	13
351	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 325.	4.4	0
352	Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology, 2016, 63, 2019-2031.	7.3	158
353	A randomized open label study of â€imipenem vs. cefepime' in spontaneous bacterial peritonitis. Liver International, 2016, 36, 677-687.	3.9	15
354	Novel prevention strategies for bacterial infections in cirrhosis. Expert Opinion on Pharmacotherapy, 2016, 17, 689-701.	1.8	21
355	Decompensated alcohol related liver disease: acute management. BMJ, The, 2016, 352, i124.	6.0	32
356	Mindray <scp>BC</scp> â€6800 body fluid mode, performance of nucleated cells, and differential count in ascitic and pleural fluids. International Journal of Laboratory Hematology, 2016, 38, 90-101.	1.3	13
357	Targeting Dysbiosis for the Treatment of Liver Disease. Seminars in Liver Disease, 2016, 36, 037-047.	3.6	40
358	Risk of Procedural Hemorrhage. Chest, 2016, 150, 237-246.	0.8	27
359	Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. Current Infectious Disease Reports, 2016, 18, 4.	3.0	8
360	Cell Population Data and reflex testing rules of cell analysis in pleural and ascitic fluids using body fluid mode on Sysmex XN-9000. Clinica Chimica Acta, 2016, 452, 92-98.	1.1	27

#	Article	IF	CITATIONS
361	Antimicrobials in Cirrhotic Patients AfterÂUpper Gastrointestinal Hemorrhage: One Size No Longer Fits All. Clinical Gastroenterology and Hepatology, 2016, 14, 324-325.	4.4	1
362	Does Albumin Infusion Reduce Renal Impairment and Mortality in Patients With Spontaneous Bacterial Peritonitis?. Annals of Emergency Medicine, 2016, 67, 458-459.	0.6	6
363	Albumin in chronic liver disease: structure, functions and therapeutic implications. Hepatology International, 2016, 10, 124-132.	4.2	137
364	Rifaximin: A reasonable alternative for norfloxacin in the prevention of spontaneous bacterial peritonitis in patients with HCV-related liver cirrhosis. Alexandria Journal of Medicine, 2016, 52, 219-226.	0.6	11
365	Reflex Testing Rules for Cell Count and Differentiation of Nucleated Elements in Pleural and Ascitic Fluids on Sysmex XE-5000. Journal of the Association for Laboratory Automation, 2016, 21, 297-304.	2.8	14
366	Age-related Morbidity and Mortality After Transjugular Intrahepatic Portosystemic Shunts. Journal of Clinical Gastroenterology, 2017, 51, 360-363.	2.2	11
367	Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites. Hepatology Research, 2017, 47, E14-E21.	3.4	23
368	Surveillance for liver complications after the Fontan procedure. Congenital Heart Disease, 2017, 12, 124-132.	0.2	59
369	Mastro Adamo, the Counterfeiter of Coins, had cirrhosis as described in Dante's Inferno (13th century) Tj ETQqC	0 0 <u>0 r</u> gBT	Overlock 10
370	Nosocomial and Community-Acquired Spontaneous Bacterial Peritonitis in patients with liver cirrhosis in China: Comparative Microbiology and Therapeutic Implications. Scientific Reports, 2017, 7, 46025.	3.3	33
371	Determinants of large drain losses early after pediatric liver transplantation. Pediatric Transplantation, 2017, 21, e12932.	1.0	6
372	Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention. Digestive Diseases, 2017, 35, 402-410.	1.9	23
373	Alfapump $\hat{A}^{\otimes}$ system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. Journal of Hepatology, 2017, 67, 940-949.	3.7	85
374	Effect of hospital-wide interventions to optimize albumin use in a tertiary hospital. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 704-709.	1.5	5
375	Prevalence, Clinical Profile, and Outcome of Ascitic Fluid Infection in Children With Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 194-199.	1.8	21
376	Effects of alfapumpâ, \$\phi\$ system on kidney and circulatory function in patients with cirrhosis and refractory ascites. Liver Transplantation, 2017, 23, 583-593.	2.4	37
377	Peri-procedural use of anticoagulants in radiology: an evidence-based review. Abdominal Radiology, 2017, 42, 1556-1565.	2.1	13
378	Cystic Fibrosis-related cirrhosis. Journal of Cystic Fibrosis, 2017, 16, S50-S61.	0.7	58

#	Article	IF	CITATIONS
379	<i>Clostridium tertium</i> Peritonitis and Concurrent Bacteremia in a Patient With a History of Alcoholic Cirrhosis. Journal of Investigative Medicine High Impact Case Reports, 2017, 5, 232470961773145.	0.6	5
380	Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure. Medicine (United States), 2017, 96, e8057.	1.0	30
381	Peritoneal Dialysis Catheters to Treat Refractory Non-Malignant Ascites. Peritoneal Dialysis International, 2017, 37, 481-482.	2.3	4
382	Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2017, 29, 1109-1117.	1.6	32
383	Role of Cystatin C and glomerular filtration rate in diagnosis of kidney impairment in hepatic cirrhosis patients. Medicine (United States), 2017, 96, e6949.	1.0	17
384	Albumin Use in Patients With Cirrhosis in France: Results of the "ALBU-LIVE―Survey. Journal of Clinical Gastroenterology, 2017, 51, 831-838.	2.2	22
385	Clinical value of urinary retinolâ€'binding protein in ascites due to cirrhosis. Experimental and Therapeutic Medicine, 2017, 14, 5228-5234.	1.8	0
386	Bacterial infections in acute variceal hemorrhage despite antibioticsâ€"a multicenter study of predictors and clinical impact. United European Gastroenterology Journal, 2017, 5, 1090-1099.	3.8	15
387	The Therapeutic use of human albumin in cancer patients' management. Critical Reviews in Oncology/Hematology, 2017, 120, 203-209.	4.4	48
388	Epidemiology and management of healthcare-associated bloodstream infections in non-neutropenic immunosuppressed patients: a review of the literature. Therapeutic Advances in Infectious Disease, 2017, 4, 171-191.	1.8	5
389	Comparison of clinical characteristics and outcomes of spontaneous bacterial peritonitis and culture negative neutrocytic ascites. Scandinavian Journal of Gastroenterology, 2017, 52, 199-203.	1.5	19
390	Prognostic significance of insulin-like growth factor-l serum levels in acute decompensation of cirrhosis. Biomarkers, 2017, 22, 127-132.	1.9	4
391	Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema. Hepatology Research, 2017, 47, 542-557.	3.4	23
392	Treatment for cirrhotic ascites. Hepatology Research, 2017, 47, 166-177.	3.4	24
393	Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 852-858.	2.8	48
394	Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterology Report, 2017, 5, 127-137.	1.3	68
395	Fontan-Associated Liver Disease. Journal of the American College of Cardiology, 2017, 70, 3173-3194.	2.8	150
397	Evidence-based Guidelines for the Use of Albumin Products Japan Society of Transfusion Medicine and Cell Therapy. Japanese Journal of Transfusion and Cell Therapy, 2017, 63, 641-663.	0.2	3

#	Article	IF	CITATIONS
398	Do We Need to Change the Treatment Strategy for Spontaneous Bacterial Peritonitis in Patients with Advanced Cirrhosis?. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2017, 69, 93.	0.4	0
399	<i>Pasteurella multocida</i> Bacteremia and Peritonitis in a Patient With Cirrhosis: A Life-Threatening Case From a Prick of a Cactus. Journal of Investigative Medicine High Impact Case Reports, 2017, 5, 232470961772610.	0.6	4
400	Hepatorenal syndrome: Update on diagnosis and therapy. World Journal of Hepatology, 2017, 9, 293.	2.0	40
401	Non-pharmacological Treatment of Ascites. , 2017, , .		0
402	Ascites: Causes, Diagnosis, and Treatment. , 0, , .		3
403	Spontaneous bacterial peritonitis by Clostridium species and antimicrobial therapy. Przeglad Gastroenterologiczny, 2017, 4, 313-314.	0.7	0
404	Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study. World Journal of Gastroenterology, 2017, 23, 8062-8072.	3.3	21
405	A Randomized Controlled Trial of Procedural Techniques for Large Volume Paracentesis. Annals of Hepatology, 2017, 16, 279-284.	1.5	10
406	Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis. World Journal of Hepatology, 2017, 9, 1278-1285.	2.0	22
407	Patients with refractory ascites treated with alfapump $\hat{A}^{\otimes}$ system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. Quality of Life Research, 2018, 27, 1513-1520.	3.1	30
408	Homocysteine: a new diagnostic marker in spontaneous bacterial peritonitis. European Journal of Gastroenterology and Hepatology, 2018, 30, 779-785.	1.6	17
409	Chronic Liver Failure and Hepatic Cirrhosis. , 2018, , 21-39.		1
410	To salt or not to salt?â€"That is the question in cirrhosis. Liver International, 2018, 38, 1148-1159.	3.9	27
411	Serum <scp><i>Wisteria floribunda</i></scp> agglutininâ€positive Macâ€2â€binding protein evaluates liver function and predicts prognosis in liver cirrhosis. Journal of Digestive Diseases, 2018, 19, 242-253.	1.5	7
412	Postâ€paracentesis hemoperitoneum â€" Time to become more careful!. Liver International, 2018, 38, 1698-1698.	3.9	1
413	ACG Clinical Guideline: Alcoholic Liver Disease. American Journal of Gastroenterology, 2018, 113, 175-194.	0.4	530
414	Point-of-Care Ultrasound in the Intensive Care Unit. Clinics in Chest Medicine, 2018, 39, 79-97.	2.1	35
415	Anesthetic and Perioperative Considerations in Liver Disease (Non-Transplant)., 2018,, 255-267.		0

#	Article	IF	CITATIONS
416	Gastrointestinal and Hepatic Physiology in Liver Disease., 2018,, 45-51.		0
417	Editorial: alfapump—an alternative to largeâ€volume paracentesis for patients with refractory ascites?. Alimentary Pharmacology and Therapeutics, 2018, 47, 139-140.	3.7	2
418	Management of decompensated cirrhosis. Clinical Medicine, 2018, 18, s60-s65.	1.9	52
419	Diagnóstico por imagen de la hipertensión portal. Radiologia, 2018, 60, 290-300.	0.5	1
420	The Role of Ultrasound-Guided Therapeutic Paracentesis in an Outpatient Transitional Care Program: A Case Series. American Journal of Hospice and Palliative Medicine, 2018, 35, 1256-1260.	1.4	9
421	The toxicity and efficacy evaluation of different fractions of Kansui fry-baked with vinegar on Walker-256 tumor-bearing malignant ascites effusion rats and normal rats. Journal of Ethnopharmacology, 2018, 219, 257-268.	4.1	29
422	New Developments in Hepatorenal Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 162-177.e1.	4.4	71
423	Predictors of Mortality in Cirrhosis Inpatients With Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2018, 52, 747-751.	2.2	20
424	Pharmacological Therapies for Hepatorenal Syndrome. Journal of Clinical Gastroenterology, 2018, 52, 360-367.	2.2	36
425	Prevalence and Impact of Bacterial Infections in Children With Liver Disease—A Prospective Study. Journal of Clinical and Experimental Hepatology, 2018, 8, 35-41.	0.9	11
426	Management of ascites and hepatorenal syndrome. Hepatology International, 2018, 12, 122-134.	4.2	62
427	Current management of refractory ascites in patients with cirrhosis. Journal of International Medical Research, 2018, 46, 1138-1145.	1.0	18
428	Continuous ambulatory peritoneal dialysis, ascitic and pleural body fluids evaluation with the Mindray <scp>BC</scp> â€6800 hematology analyzer. Journal of Clinical Laboratory Analysis, 2018, 32, .	2.1	9
429	KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. Clinical and Molecular Hepatology, 2018, 24, 230-277.	8.9	49
430	Prognostic Significance of The New Criteria for Acute Kidney Injury in Cirrhosis. Annals of Hepatology, 2018, 17, 461-469.	1.5	8
431	EVIDENCE-BASED GUIDELINES FOR THE USE OF ALBUMIN PRODUCTS (SECOND EDITION). Japanese Journal of Transfusion and Cell Therapy, 2018, 64, 700-717.	0.2	7
432	Paracentesis: datos sobre la correcta utilizaci $\tilde{A}^3$ n. Revista Universitas Medica, 2018, 59, .	0.1	0
433	Intestinal Microbiome and the Liver. , 2018, , 37-65.e6.		0

#	Article	IF	CITATIONS
434	Ascites and Hyponatremia., 2018,, 220-232.e4.		1
435	Renal Failure in Cirrhosis. , 2018, , 262-280.e5.		1
436	Critical Care Management of Gastrointestinal Bleeding and Ascites in Liver Failure. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 566-577.	2.1	4
437	Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology, 2018, 155, 1816-1827.e9.	1.3	113
438	Assessing adherence to current national guidelines for appropriate albumin use at an academic medical center. Pharmacy Practice, 2018, 16, 1190.	1.5	2
439	An Unusual Cause of Abdominal Ascites. Case Reports in Gastroenterology, 2018, 12, 420-424.	0.6	2
440	Fibrosis Staging Using Direct Serum Biomarkers is Influenced by Hepatitis Activity Grading in Hepatitis C Virus Infection. Journal of Clinical Medicine, 2018, 7, 267.	2.4	16
441	Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA. Journal of Global Antimicrobial Resistance, 2018, 15, 41-47.	2.2	9
442	Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. American Journal of Gastroenterology, 2018, 113, 1167-1176.	0.4	23
443	Xuebijing Injection Combined with Antibiotics for the Treatment of Spontaneous Bacterial Peritonitis in Liver Cirrhosis: A Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-10.	1.2	5
444	Clinical Assessment and Management of Portal Hypertension. Seminars in Interventional Radiology, 2018, 35, 153-159.	0.8	11
445	Imaging diagnosis of portal hypertension. Radiologia, 2018, 60, 290-300.	0.5	0
446	Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure. Visceral Medicine, 2018, 34, 261-268.	1.3	15
447	Current and emerging pharmacotherapy for the treatment of bacterial peritonitis. Expert Opinion on Pharmacotherapy, 2018, 19, 1317-1325.	1.8	9
448	Hemodynamic Evaluation of Nonselective $\hat{l}^2$ -Blockers in Patients with Cirrhosis and Refractory Ascites. Gastroenterology Research and Practice, 2018, 2018, 1-7.	1.5	5
449	Ascites and Spontaneous Bacterial Peritonitis. , 2018, , 182-196.		0
450	Current Management of Hepatic Encephalopathy. American Journal of Gastroenterology, 2018, 113, 1600-1612.	0.4	45
451	Combination of PCT, sNFI and dCHC for the diagnosis of ascites infection in cirrhotic patients. BMC Infectious Diseases, 2018, 18, 389.	2.9	4

#	Article	IF	CITATIONS
452	Amplification of bacterial genomic DNA from all ascitic fluids with a highly sensitive polymerase chain reaction. Molecular Medicine Reports, 2018, 18, 2117-2123.	2.4	7
453	Clinical and bacteriological features and prognosis of ascitic fluid infection in Chinese patients with cirrhosis. BMC Infectious Diseases, $2018, 18, 253$ .	2.9	17
454	Management of Coagulation and Anticoagulation in Liver Transplantation Candidates. Liver Transplantation, 2018, 24, 1119-1132.	2.4	31
455	Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-10.	1.9	22
456	Life-long antimicrobial therapy: where is the evidence?. Journal of Antimicrobial Chemotherapy, 2018, 73, 2601-2612.	3.0	20
459	Refractory Ascites in Liver Cirrhosis. American Journal of Gastroenterology, 2019, 114, 40-47.	0.4	46
460	Adjusted Intensive Care Infection Score (ICISÎ")â€"A new approach for prediction of ascitic fluid infection in patients with cirrhosis. Digestive and Liver Disease, 2019, 51, 104-111.	0.9	0
461	Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Schistosomiasis-Induced Liver Fibrosis. CardioVascular and Interventional Radiology, 2019, 42, 1760-1770.	2.0	13
462	Spontaneous fungal peritonitis: Micro-organisms, management and mortality in liver cirrhosis-A systematic review. World Journal of Hepatology, 2019, 11, 596-606.	2.0	15
463	Causes and Clinical Profiles of Ascites at University of Gondar Hospital, Northwest Ethiopia: Institution-Based Cross-Sectional Study. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-8.	1.9	6
464	The Liver in Systemic Illness., 2019,, 361-396.		1
465	A survey of practice in management of malignancy-related ascites in Japan. PLoS ONE, 2019, 14, e0220869.	2.5	5
466	The Role of 16s Ribosomal RNA in Diagnosing Spontaneous Bacterial Peritonitis. Journal of Molecular Biomarkers & Diagnosis, 2019, 10, .	0.4	1
467	Infection in cirrhosis: A prospective study. Annals of Hepatology, 2019, 18, 862-868.	1.5	15
468	Discovering Medication Patterns for High-Complexity Drug-Using Diseases Through Electronic Medical Records. IEEE Access, 2019, 7, 125280-125299.	4.2	3
469	Combination of vial culture and broad-range PCR for the diagnosis of spontaneous bacterial peritonitis: experience in a Greek tertiary care hospital. New Microbes and New Infections, 2019, 28, 1-5.	1.6	5
470	Chinese guidelines on the management of ascites and its related complications in cirrhosis. Hepatology International, 2019, 13, 1-21.	4.2	45
471	Emerging Gram†positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: A retrospective study. Experimental and Therapeutic Medicine, 2019, 17, 4568-4576.	1.8	7

#	Article	IF	CITATIONS
472	Current and future pharmacological therapies for managing cirrhosis and its complications. World Journal of Gastroenterology, 2019, 25, 888-908.	3.3	36
473	Design and rationale of a randomized–controlled trial of home-delivered meals for the management of symptomatic ascites: the SALTYFOOD trial. Gastroenterology Report, 2019, 7, 146-149.	1.3	5
475	Infections in Cirrhosis. Current Treatment Options in Gastroenterology, 2019, 17, 254-270.	0.8	34
476	ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs. Journal of Veterinary Internal Medicine, 2019, 33, 1173-1200.	1.6	77
477	Comparative efficacy of longâ€term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis. Liver International, 2019, 39, 1448-1458.	3.9	20
478	Paracentesis-induced acute kidney injury in decompensated cirrhosis – prevalence and predictors. Clinical and Experimental Hepatology, 2019, 5, 55-59.	1.3	7
479	Pretreatment risk management of a novel nomogram model for prediction of thoracoabdominal extrahepatic metastasis in primary hepatic carcinoma. Journal of Translational Medicine, 2019, 17, 117.	4.4	8
480	Albumin in Cirrhosis: More Than a Colloid. Current Treatment Options in Gastroenterology, 2019, 17, 231-243.	0.8	6
481	Clinical Pharmacology in Diuretic Use. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1248-1257.	4.5	97
483	Treatment of Spontaneous Bacterial Peritonitis. , 2019, , 517-522.		0
484	Sensitivity of a bedside reagent strip for the detection of spontaneous bacterial peritonitis in ED patients with ascites. American Journal of Emergency Medicine, 2019, 37, 2155-2158.	1.6	3
485	Efficacy and safety of umbilical therapy with the traditional Chinese medicine formulation Lishui Xiaogu cataplasm for cirrhotic ascites: protocol for a randomized controlled trial. Trials, 2019, 20, 127.	1.6	4
486	Clinical audit to determine efficacy of daily infusion of low dose of 20% albumin in combination with antibiotics in patients with spontaneous bacterial peritonitis. Clinical and Experimental Hepatology, 2019, 5, 301-307.	1.3	3
487	Acupuncture for chronic hepatitis B. The Cochrane Library, 2019, 8, CD013107.	2.8	5
488	Norfloxacin, ciprofloxacin, trimethoprim–sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis. European Journal of Gastroenterology and Hepatology, 2019, 31, 905-910.	1.6	9
489	Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. The Cochrane Library, 2019, 6, CD004039.	2.8	13
490	When to Refer for Liver Transplantation. American Journal of Gastroenterology, 2019, 114, 7-10.	0.4	3
491	Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis. Hepatology Research, 2019, 49, 82-95.	3.4	31

#	Article	IF	Citations
492	Longâ€term albumin administration in patients with decompensated cirrhosis. It is time for a reappraisal. Liver International, 2019, 39, 45-48.	3.9	9
493	Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence. Current Medical Research and Opinion, 2019, 35, 859-868.	1.9	17
494	Survival and predictors of outcome among patients with decompensated liver disease in a nonâ€liver transplant intensive care unit. Pessimism is historical and unjustified. Internal Medicine Journal, 2019, 49, 745-752.	0.8	0
495	Ascitic cholesterol is superior to serumâ€ascites albumin gradient in the detection of nonâ€portal hypertensive ascites and the diagnosis of mixed ascites. Alimentary Pharmacology and Therapeutics, 2019, 49, 91-98.	3.7	15
496	Liver Failure in the ICU., 2019,, 87-99.		0
497	Intensive Diuresis and Ultrafiltration., 2019,, 402-408.e2.		0
498	Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 1175-1182.e2.	4.4	10
499	Pro: The Role of Albumin in Pre–Liver Transplant Management. Liver Transplantation, 2019, 25, 128-134.	2.4	9
500	AGA Clinical Practice Update on Surgical Risk AssessmentÂand Perioperative Management in Cirrhosis: Expert Review. Clinical Gastroenterology and Hepatology, 2019, 17, 595-606.	4.4	79
501	Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. European Journal of Gastroenterology and Hepatology, 2019, 31, 345-351.	1.6	15
502	Vitamin E Improves Transplantâ€Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology, 2020, 71, 495-509.	7.3	117
503	Ascitic fluid total protein, a useful marker in nonâ€portal hypertensive ascites. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 271-277.	2.8	10
504	Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. Journal of Gastroenterology, 2020, 55, 217-226.	5.1	16
505	Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows. Neurotherapeutics, 2020, 17, 127-141.	4.4	14
506	Combination and sequential evaluation of acute-on-chronic liver failure (ACLF) and hyponatremia and prognosis in cirrhotic patients. Digestive and Liver Disease, 2020, 52, 91-97.	0.9	10
507	Transfusion strategies in patients with cirrhosis. European Journal of Haematology, 2020, 104, 15-25.	2.2	29
508	Effect of Nonselective $\hat{I}^2$ -Blockers on Mortality in Patients With End-Stage Cirrhosis. Annals of Pharmacotherapy, 2020, 54, 322-330.	1.9	2
509	Micronutrients in Liver Disease: Roles, Risk Factors for Deficiency, and Recommendations for Supplementation. Nutrition in Clinical Practice, 2020, 35, 50-62.	2.4	43

#	Article	IF	Citations
510	Kansuiphorin C and Kansuinin A ameliorate malignant ascites by modulating gut microbiota and related metabolic functions. Journal of Ethnopharmacology, 2020, 249, 112423.	4.1	7
511	Change in antibiotic regimen for emerging multidrug resistance in nosocomial ascitic fluid infection. Hepatology International, 2020, 14, 1-4.	4.2	9
512	Ascitis. Medicine, 2020, 13, 327-337.	0.0	0
513	Complicaciones de la cirrosis hepática. Medicine, 2020, 13, 316-326.	0.0	O
514	Current Status and Prospects of Spontaneous Peritonitis in Patients with Cirrhosis. BioMed Research International, 2020, 2020, 1-12.	1.9	5
515	Diagnostic body fluid testing. , 2020, , 469-486.		1
516	Medically tailored meals for the management of symptomatic ascites: the SALTYFOOD pilot randomized clinical trial. Gastroenterology Report, 2020, 8, 453-456.	1.3	4
517	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. Digestive Diseases and Sciences, 2021, 66, 3612-3618.	2.3	15
518	Shortcomings in Design and Analysis of Clinical Studies on Bleeding and Thrombosis in Patients with Cirrhosis. Seminars in Thrombosis and Hemostasis, 2020, 46, 665-672.	2.7	4
519	Chylous Ascites and Lymphoceles: Evaluation and Interventions. Seminars in Interventional Radiology, 2020, 37, 274-284.	0.8	11
520	Ascitic calprotectin for the diagnosis of spontaneous bacterial peritonitis: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2020, 32, 1075-1083.	1.6	1
521	Feasibility and Procedural Safety of alfapump System Implantation by IR: Experience from the MOSAIC Study, a Multicenter, Open-Label Prospective Study in Cirrhotic Patients with Refractory Ascites. Journal of Vascular and Interventional Radiology, 2020, 31, 1256-1262.e3.	0.5	5
522	Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ, The, 2020, 370, m2687.	6.0	116
523	Palliative Interventions in Patients With Cirrhosis With Refractory Ascites and Hepatic Hydrothorax: Who, What, and When?. Clinical Liver Disease, 2020, 16, 63-65.	2.1	0
524	Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines?. International Journal of Hepatology, 2020, 2020, 1-7.	1.1	4
525	Acute on Chronic Liver Failure. Clinics in Liver Disease, 2020, 24, 521-534.	2.1	4
526	Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity. ESMO Open, 2020, 5, e000695.	<b>4.</b> 5	10
527	Xiaozhang Tie Improves Intestinal Motility in Rats With Cirrhotic Ascites by Regulating the Stem Cell Factor/c-kit Pathway in Interstitial Cells of Cajal. Frontiers in Pharmacology, 2020, 11, 1.	3.5	299

#	Article	IF	CITATIONS
529	Portal Hypertensive Ascites: Current Status. Current Hepatology Reports, 2020, 19, 226-234.	0.9	1
530	Review on Ascites in Pets., 0,,.		2
531	Outcomes After Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients 70 Years and Older. Journal of Clinical Medicine, 2020, 9, 381.	2.4	7
532	Limited effects of antibiotic prophylaxis in patients with Child–Pugh class A/B cirrhosis and upper gastrointestinal bleeding. PLoS ONE, 2020, 15, e0229101.	2.5	8
533	Evaluation of serum kallistatin level as a predictor of esophageal varices in cirrhotic patients. Alexandria Journal of Medicine, 2020, 56, 21-26.	0.6	0
534	Improvement in Quality of Life and Decrease in Largeâ€Volume Paracentesis Requirements With the Automated Lowâ€Flow Ascites Pump. Liver Transplantation, 2020, 26, 651-661.	2.4	19
535	A population-based cohort study of mortality of intensive care unit patients with liver cirrhosis. BMC Gastroenterology, 2020, 20, 15.	2.0	11
536	Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study. BMC Gastroenterology, 2020, 20, 30.	2.0	20
537	Acceptance and use of a smartphone application in cirrhosis. Liver International, 2020, 40, 1556-1563.	3.9	32
538	Do Nutritional Interventions Improve the Outcomes of Patients with Cirrhosis and Ascites: a Systematic Review of Randomized Trials. Current Hepatology Reports, 2020, 19, 71-77.	0.9	6
539	Peritoneal tuberculosis mimicking carcinomatous ascites in a child living in a low prevalence country: a case report. Italian Journal of Pediatrics, 2020, 46, 49.	2.6	2
540	Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Anti-Enterococcal Therapy for Intra-Abdominal Infection. Surgical Infections, 2021, 22, 131-143.	1.4	7
541	Discrimination of ascitic fluid infection in malignant ascites by polymorphonuclear neutrophil ratio and count: Investigating the validity of count ≥250/mm 3 as the oneâ€sizeâ€fitsâ€all criterion. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e87-e93.	1.1	0
542	Keeping Patients with End-Stage Liver Disease Alive While Awaiting Transplant. Clinics in Liver Disease, 2021, 25, 103-120.	2.1	5
543	Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis. Hepatology, 2021, 73, 2429-2440.	7.3	21
544	Fibrosis and hepatic regeneration mechanism. Translational Gastroenterology and Hepatology, 2022, 7, 9-9.	3.0	8
545	Lymphocyte to Monocyte Ratio and C-Reactive Protein Combination as the Best Simple Predictor of Treatment Response in Cirrhotic Patients With Culture Negative Neutrocytic Ascites. Sisli Etfal Hastanesi Tip Bulteni, 2021, 56, 77-83.	0.3	2
547	Cirrhotics with monocyte chemotactic protein 1 polymorphism are at higher risk for developing spontaneous bacterial peritonitis – A cohort study. Journal of Clinical and Translational Research, 0,	0.3	0

#	Article	IF	CITATIONS
548	Liver and Biliary Disease of Pregnancy and Anesthetic Implications: A Review. Anesthesia and Analgesia, 2021, 133, 80-92.	2.2	2
549	Cryptococcal peritonitis in patients on the liver transplant waitlist: Reporting two cases with opposite outcomes. Transplant Infectious Disease, 2021, 23, e13583.	1.7	0
550	The role of prophylactic antibiotics in hepatitis B virus-related acute-on-chronic liver failure patients at risk of bacterial infection: a retrospective study. Infectious Diseases of Poverty, 2021, 10, 44.	3.7	2
551	Concordance of 24- and 48-h diagnostic follow-up ascitic fluid polymorphonuclear leukocyte count in the guidance of the antibiotic therapy in spontaneous bacterial peritonitis. Egyptian Liver Journal, $2021,11,\ldots$	0.6	0
553	ACR Appropriateness Criteria $\hat{A}^{@}$ Radiologic Management of Portal Hypertension. Journal of the American College of Radiology, 2021, 18, S153-S173.	1.8	4
554	The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone. Seminars in Liver Disease, 2021, 41, 213-224.	3.6	13
555	Evolution, progress, and prospects of research on transjugular intrahepatic portosystemic shunt applications. Journal of Interventional Medicine, 2021, 4, 57-61.	0.5	1
556	Development and Validation of a Prognostic Model for One-year Survival of Cirrhosis Patients with First-ever Spontaneous Bacterial Peritonitis. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	1.4	1
557	A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2021, 33, e587-e593.	1.6	1
558	Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74, 1014-1048.	7.3	311
559	Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. International Journal of Molecular Sciences, 2021, 22, 5582.	4.1	3
560	ACLF and Liver Transplantation. Current Treatment Options in Gastroenterology, 2021, 19, 473-482.	0.8	0
561	Infections in Cirrhosis: A Guide for the Clinician. American Journal of Medicine, 2021, 134, 727-734.	1.5	3
562	No evidence of benefit of routine ascitic fluid analysis in refractory ascites undergoing therapeutic paracentesis. European Journal of Gastroenterology and Hepatology, 2021, 33, 942-942.	1.6	1
563	Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites. Cureus, 2021, 13, e15403.	0.5	0
564	A Mixed Case Report of Long-Term Management of Ascites and Anasarca From Liver Disease on a Remote Pacific Island. Wilderness and Environmental Medicine, 2021, 32, 230-234.	0.9	0
565	Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial. Frontiers in Pharmacology, 2021, 12, 675948.	3.5	22
566	Puncture needle with a hard plastic sheath and plastic wings minimizes repuncture attempts in ultrasound-guided paracentesis: a retrospective case-control study. Yeungnam University Journal of Medicine, 2022, 39, 18-23.	1.4	0

#	ARTICLE	IF	CITATIONS
568	The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin. Liver Transplantation, 2021, 27, 1191-1202.	2.4	23
569	Changes in Ascitic Fluid Polymorphonuclear Cell Count After Antibiotics Are Associated With Mortality in Spontaneous Bacterial Peritonitis. Clinical Gastroenterology and Hepatology, 2022, 20, e1201-e1204.	4.4	4
570	Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. Cancers, 2021, 13, 4318.	3.7	47
571	Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice. World Journal of Hepatology, 2021, 13, 840-852.	2.0	1
572	Percutaneous Image-Guided Interventions Including Solid Organ Biopsies., 2021,, 361-375.		0
573	Changing Trends in Liver Cirrhosis Etiology and Severity in Korea: the Increasing Impact of Alcohol. Journal of Korean Medical Science, 2021, 36, e145.	2.5	8
574	CLIF-C AD Score Predicts Development of Acute Decompensations and Survival in Hospitalized Cirrhotic Patients. Digestive Diseases and Sciences, 2021, 66, 4525-4535.	2.3	10
577	Disorders of the Liver and Biliary Tract. , 2010, , 1153-1171.		4
578	Liver Disease. , 2012, , 1637-1693.		4
580	Paracentesis-induced circulatory dysfunction: are there albumin alternatives?. Egyptian Liver Journal, 2020, 10, .	0.6	3
581	Microbial Infections as a Trigger for Acute-on-Chronic Liver Failure: A Review. Medical Science Monitor, 2019, 25, 4773-4783.	1.1	7
582	The need for antibiotic stewardship and treatment standardization in the care of cirrhotic patients with spontaneous bacterial peritonitis – a retrospective cohort study examining the effect of ceftriaxone dosing. F1000Research, 2014, 3, 57.	1.6	9
583	Constrictive pericarditis as a cause of refractory ascites after liver transplantation: A case report. World Journal of Clinical Cases, 2019, 7, 3266-3270.	0.8	2
584	Constrictive pericarditis as a cause of refractory ascites after liver transplantation: A case report. World Journal of Clinical Cases, 2019, 7, 3267-3270.	0.8	1
585	Ascitic Microbiota Composition Is Correlated with Clinical Severity in Cirrhosis with Portal Hypertension. PLoS ONE, 2013, 8, e74884.	2.5	36
586	Impact of Physician Specialty on Quality Care for Patients Hospitalized with Decompensated Cirrhosis. PLoS ONE, 2015, 10, e0123490.	2.5	12
587	Voltammetric analysis for distinguishing portal hypertension-related from malignancy-related ascites: A proof of concept study. PLoS ONE, 2020, 15, e0233350.	2.5	5
589	Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. Reviews on Recent Clinical Trials, 2019, 14, 129-135.	0.8	6

#	Article	IF	CITATIONS
590	Post-hepatectomy Refractory Ascites in Cirrhotic Patients with Hepatocellular Carcinoma: Risk Factor Analysis to Overcome this Problematic Complication. Anticancer Research, 2017, 37, 1381-1386.	1.1	12
591	Una mirada actual a la peritonitis bacteriana espontaìnea. Revista Colombiana De Gastroenterologia, 2016, 30, 315.	0.2	2
592	Clinical use of albumin. Blood Transfusion, 2013, 11 Suppl 4, s18-25.	0.4	59
593	Liver Cirrhosis: Modern Approach to the Problem. Lviv Clinical Bulletin, 2020, 3, 53-61.	0.2	1
594	The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction. Clinical and Molecular Hepatology, 2015, 21, 365.	8.9	15
595	Are we providing patient-centered care? Preferences about paracentesis and thoracentesis procedures. Patient Experience Journal, 2014, 1, 94-103.	0.7	4
596	How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World Journal of Gastroenterology, 2011, 17, 3479.	3.3	26
597	Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count. World Journal of Gastroenterology, 2013, 19, 2028.	3.3	43
598	Risk factors and outcome of bacterial infections in cirrhosis. World Journal of Gastroenterology, 2014, 20, 2542.	3.3	102
599	Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites. World Journal of Gastroenterology, 2014, 20, 2374.	3.3	26
600	Spontaneous fungal peritonitis: Epidemiology, current evidence and future prospective. World Journal of Gastroenterology, 2016, 22, 7742.	3.3	35
601	Current approaches to the management of patients with cirrhotic ascites. World Journal of Gastroenterology, 2019, 25, 3738-3752.	3.3	20
602	A quick screening model for symptomatic bacterascites in cirrhosis. Saudi Journal of Gastroenterology, 2016, 22, 282.	1.1	5
603	Assessment of calprotectin in ascitic fluid as a marker for spontaneous bacterial peritonitis diagnosis in cirrhotic patients. The Egyptian Journal of Internal Medicine, 2018, 30, 223-230.	0.9	4
604	Propofol <i>vs</i> midazolam sedation for elective endoscopy in patients with cirrhosis: A systematic review and meta-analysis of randomized controlled trials. World Journal of Gastrointestinal Endoscopy, 2020, 12, 241-255.	1.2	12
605	Low incidence of spontaneous bacterial peritonitis in asymptomatic cirrhotic outpatients. World Journal of Hepatology, 2013, 5, 104.	2.0	17
606	Spontaneous bacterial peritonitis. Revista Espanola De Enfermedades Digestivas, 2011, 103, 255-263.	0.3	14
607	A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide. Pharmacy Practice, 2013, 11, 44-50.	1.5	16

#	Article	IF	CITATIONS
608	Cirrhosis with ascites: Is the presence of hemorrhagic ascites an indicator of poor prognosis?. Turkish Journal of Gastroenterology, 2016, 27, 349-353.	1.1	6
609	Clinical Features of Refractory Ascites in Outpatients. Clinics, 2017, 72, 405-410.	1.5	4
610	Refractory ascitesâ€"the contemporary view on pathogenesis and therapy. PeerJ, 2019, 7, e7855.	2.0	4
611	Emergency Management of Spontaneous Bacterial Peritonitis – A Clinical Review. Cureus, 2018, 10, e2253.	0.5	10
612	Ascitic Fluid High Sensitive C-Reactive Protein (hs-CRP). A Prognostic Marker in Cirrhosis with Spontaneous Bacterial Peritonitis. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, OC20-4.	0.8	9
613	Difficult to treat spontaneous bacterial peritonitis. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2013, 34, 7-13.	0.0	19
614	Constrictive pericarditis diagnosed following liver transplantation. Marmara Medical Journal, 0, , .	0.8	0
615	Utility of neutrophil CD64 in distinguishing bacterial infection from inflammation in severe alcoholic hepatitis fulfilling SIRS criteria. Scientific Reports, 2021, 11, 19726.	3.3	5
616	Spontaneous bacterial peritonitis: Few additional points. World Journal of Gastroenterology, 2009, 15, 5754.	3.3	2
617	Complications of Cirrhosis., 2010,, 524-533.		0
619	Management of Ascites and Hyponatremia. , 2011, , 411-427.		0
620	Chronic Liver Failure Management: Management of Bacterial Infections. , 2011, , 113-116.		0
621	Management of End-Stage Liver Disease and the Role of Liver Transplantation in HIV-Infected Patients., 2012, , 171-179.		0
623	KOMPLIKACIJE ALKOHOLNE BOLESTI JETRE I DIJAGNOSTIÄŒKI MARKERI. Acta Medica Medianae, 2011, , 55-61.	0.1	0
624	Cirrhosis and Ascites. , 2012, , 2049-2059.		0
627	A Complication of Paracentesis Due to Hyperfibrinolysis: Hemoperitoneum. Journal of Blood Disorders & Transfusion, 2013, , .	0.1	0
628	Successful transjugular intrahepatic portal-systemic shunt in an ineligible liver transplant patient with primary biliary cirrhosis with refractory ascites and aplastic anemia. Open Journal of Gastroenterology, 2013, 03, 1-4.	0.1	0
629	Cell-free concentrated ascites reinfusion therapy for refractory ascites associated with alcoholic liver cirrhosis. Acta Hepatologica Japonica, 2013, 54, 614-619.	0.1	0

#	Article	IF	CITATIONS
630	Aszites., 2013,, 871-882.		0
633	Clinical Aspects of Peritonitis in Peritoneal Dialysis Patient: A Single Center Experience. Soonchunhyang Medical Science, 2013, 19, 72-79.	0.0	1
634	Antibiotic Prophylaxis in Acute Variceal Hemorrhage. , 2014, , 123-133.		0
635	Comparison of abdominal puncture and diuretics during ascites treatment. Scripta Medica, 2014, 45, 51-55.	0.1	0
636	Dosing of ceftriaxone and outcomes after spontaneous bacterial peritonitis. F1000Research, 2014, 3, 57.	1.6	4
637	Hepato-renal Syndrome: Etiopathogenesis, Diagnosis and Treatment. Serbian Journal of Experimental and Clinical Research, 2014, 15, 95-100.	0.1	0
638	Diagnosis of spontaneous bacterial peritonitis. The Egyptian Journal of Internal Medicine, 2014, 26, 53-59.	0.9	3
639	Ascitic Fluid Calprotectin and Serum C-Reactive Protein as Diagnostic Markers for Spontaneous Bacterial Peritonitis. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2014, 4, 117-125.	0.1	5
640	Adherence to American Association for the Study of Liver Diseases (AASLD) Guidelines and Predictors of Readmission in Cirrhotic Patients: A Single Center Experience. Open Access Library Journal (oalib), 2015, 02, 1-8.	0.2	1
641	Peritonitis and Intraperitoneal Abscesses. , 2015, , 935-959.e4.		6
642	Palliative Care in Cirrhosis., 2015,, 337-346.		1
643	Bacterial infections in patients with liver cirrhosis. Bukovinian Medical Herald, 2015, 19, 245-253.	0.1	0
644	Percutaneous Image-Guided Interventions Including Solid Organ Biopsies., 2016,, 281-293.		0
645	Spontaneous Bacterial Peritonitis: Is It Still A Life-Threatening Issue in Cirrhosis?. Journal of Gastroenterology and Hepatology Research, 2016, 5, 2102-2111.	0.2	0
647	General Care of the Liver Patient. , 2017, , 17-25.		0
648	Association between Serum Sodium Level and Severity of Complications in Liver Cirrhosis. Journal of Medical Science and Clinical Research, 2017, 05, 17109-17125.	0.0	0
649	Anesthesia for Surgical Procedures in Cirrhotic Patients Other than Liver Transplantation: Management, Concerns, and Pitfalls. , 2017, , 57-69.		0
650	Computerized Tomography-Guided Paracentesis: An Effective Alternative to Bedside Paracentesis?. Journal of Clinical Medicine Research, 2017, 9, 92-97.	1.2	1

#	Article	IF	CITATIONS
651	Degree of Hyper-Dynamic Circulation Correlates with the Severity of Liver Disease and Predicts Poor Outcome in Spontaneous Bacterial Peritonitis Patients in Intensive Care Unit. Open Journal of Gastroenterology, 2017, 07, 105-114.	0.1	0
652	ICU Management of the Patient with Alcoholic Liver Disease. , 2017, , 589-602.		0
653	Outcomes of Albumin Use in the Treatment of Acute Hepatorenal Disorders: A Single Center Experience. Journal of Renal and Hepatic Disorders, 2017, 1, 5-10.	0.2	0
654	Comment on â€~Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites'. Journal of Clinical and Translational Hepatology, 2017, 5, 184.	1.4	2
655	The principles of management of patients with liver cirrhosis complicated by ascites. Klinicheskaia Meditsina, 2017, 95, 789-796.	0.1	3
656	Cardiohepatic Interactions. , 2018, , 514-522.		0
657	Herz-Kreislauf-System. , 2018, , 145-201.		0
658	Vascular Ultrasonography: A Novel Method to Reduce Paracentesis Related Major Bleeding. Journal of Hospital Medicine, 2018, 13, 30-33.	1.4	3
660	OBSOLETE: Cardiohepatic Interactions. , 2018, , .		0
661	COMPARATIVE STUDY OF ASCITIC FLUID AND SERUM LEVELS OF CALPROTECTIN, PROCALCITONIN AND ENDOCAN IN PATIENTS WITH LIVER CIRRHOSIS FOR EARLY DIAGNOSIS AND PREDICTION OF SPONTANEOUS BACTERIAL PERITONITIS. Al Azhar Medical Journal = Majallat Al-Tibb Al-Azhar, 2018, 47, 257-270.	0.1	0
662	EFFICACY OF CELL-FREE AND CONCENTRATED ASCITES FOR AUTOLOGOUS ALBUMIN PRODUCTS. Japanese Journal of Transfusion and Cell Therapy, 2018, 64, 631-640.	0.2	1
663	Necessity of continuous tolvaptan administration based on the results of a placebo-control trial: A post-hoc analysis based on the pivotal Phase 3 trial. Acta Hepatologica Japonica, 2018, 59, 633-640.	0.1	0
664	Unresolved issues in the prophylaxis of bacterial infections in cirrhosis patients. World Journal of Hepatology, 2018, 10, 892-897.	2.0	1
665	Value of ascitic fluid lipids in the differentiation between cirrhotic and malignant ascites. Clinical Cancer Investigation Journal, 2019, 8, 205.	0.9	0
666	A Case of Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombosis Successfully Resected after Control of Ascites by Tolvaptan. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical) Tj ETQq0 0 0 r	gB <b>ō./</b> Øverl	octa 10 Tf 50
667	Hepatic Ascites in Liver Cirrhosis. , 2019, , 105-118.		0
668	A woman, age 35, with new-onset ascites. Cleveland Clinic Journal of Medicine, 2019, 86, 257-262.	1.3	0
669	Epidemiology and Natural History of Chronic Liver Disease. , 2020, , 1-9.		1

#	Article	IF	CITATIONS
670	Ultrasound-Guided Gastrointestinal and Genitourinary Procedures., 2020,, 179-203.		1
672	Cirrhotic ascites: A review of pathophysiology and management. Nigerian Journal of Gastroenterology and Hepatology, 2020, 12, 3.	0.2	1
674	Acute Decompensation in Chronic Liver Failure. , 2020, , 435-441.		0
675	Diagnostic Value of Serum Procalcitonin Level in HCV Cirrhotic Patients with Spontaneous Bacterial Peritonitis. Al-Azhar International Medical Journal, 2020, .	0.1	0
676	Haemorrhagic versus non haemorrhagic ascites in cirrhosis:ÂTheir relationship and impact on prognosis of liver cirrhosis. Pakistan Journal of Medical Sciences, 2020, 36, 603-608.	0.6	5
677	Applying the original model for end-stage liver disease score rather than the model for end-stage liver disease-Na score for risk stratification prior to transjugular intrahepatic portosystemic shunt procedures. European Journal of Gastroenterology and Hepatology, 2021, 33, 541-546.	1.6	5
678	A Comparison Of Manual Hemocytometry And Different Modes Of Mindray BC-6800 Hematology Analyzer For Cell Count In Peritoneal And Pleural Fluids. Dicle Medical Journal, 0, , 278-285.	0.6	0
679	Elevated neopterin levels are associated with acute-on-chronic liver failure and mortality in patients with liver cirrhosis. Digestive and Liver Disease, 2020, 52, 753-760.	0.9	1
680	Multivariate predictive model for asymptomatic spontaneous bacterial peritonitis in patients with liver cirrhosis. World Journal of Gastroenterology, 2020, 26, 4316-4326.	3.3	5
681	Microbiological Characteristics and Antibiotic Sensitivity in Patients with Nosocomial Spontaneous Bacterial Peritonitis Caused by Escherichia coli: A Multicenter Study. Infectious Microbes & Diseases, 2020, 2, 167-172.	1.3	2
682	Liver stiffness measured by virtual touch quantification predicts the occurrence of posthepatectomy refractory ascites in patients with hepatocellular carcinoma. Surgery Today, 2022, 52, 822-831.	1.5	2
683	Cirrhosis and ascites. , 2020, , C15.22.2-C15.22.2.P128.		1
684	Part 1: Disease of the Heart and Liver. Cardiology in Review, 2022, 30, 111-122.	1.4	2
685	Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial). BMJ Open Gastroenterology, 2020, 7, e000531.	2.7	21
687	STUDY OF MEAN PLATELET VOLUME VERSUS LEUCOCYTE ESTERASE AS A MARKER IN DIAGNOSIS OF SPONTANEOUS BACTERIAL PERITONITIS. Al Azhar Medical Journal = Majallat Al-Tibb Al-Azhar, 2020, 49, 69-82.	0.1	0
688	Ultrasound for Shock Evaluation, Resuscitation, and Critical Care Procedures. , 2020, , 637-686.		0
689	Post-hepatectomy tolvaptan-induced hypernatremia in a hepatocellular carcinoma patient with cirrhosis: a case report. Surgical Case Reports, 2020, 6, 61.	0.6	3
690	Analysis of ascitic fluid in differentiating transudate versus exudate - in a tertiary care centre. Indian Journal of Pathology and Oncology, 2020, 7, 137-142.	0.1	0

#	Article	IF	Citations
691	Spontaneous Bacterial Peritonitis: We Are Still Behind. Cureus, 2020, 12, e7711.	0.5	3
692	STUDY OF CELLULITIS IN CIRRHOSIS IN A TERTIARY CARE CENTER. , 2020, , 1-2.		O
695	Ascites in patients with cirrhosis. Canadian Family Physician, 2013, 59, 1297-9; e538-40.	0.4	11
696	Malnutrition in liver cirrhosis: the influence of protein and sodium. Middle East Journal of Digestive Diseases, 2013, 5, 65-75.	0.4	41
697	Are Nectarines to Blame? A Case Report and Literature Review of Spontaneous Bacterial Peritonitis Due to Listeria monocytogenes. Connecticut Medicine, 2015, 79, 31-6.	0.2	12
698	Complications of end-stage liver disease. Canadian Family Physician, 2016, 62, 44-50.	0.4	6
699	Hyponatremia and Hepatorenal Syndrome. Gastroenterology and Hepatology, 2015, 11, 220-9.	0.1	6
701	Cirrhotics with Monocyte Chemotactic Protein 1 Polymorphism are at Higher Risk for Developing Spontaneous Bacterial Peritonitis - A Cohort Study. Journal of Clinical and Translational Research, 2021, 7, 320-325.	0.3	0
702	Next- and Third-Generation Sequencing Outperforms Culture-Based Methods in the Diagnosis of Ascitic Fluid Bacterial Infections of ICU Patients. Cells, 2021, 10, 3226.	4.1	10
703	A Predictive Model for Avoiding Follow-Up Paracentesis in Spontaneous Bacterial Peritonitis. GE Portuguese Journal of Gastroenterology, $0$ , $1$ -8.	0.8	0
704	Indian College of Radiology and Imaging Evidence-Based Guidelines for Interventions in Portal Hypertension and Its Complications. Indian Journal of Radiology and Imaging, 2021, 31, 917-932.	0.8	0
705	Acute-on-Chronic Liver Failure Clinical Guidelines. American Journal of Gastroenterology, 2022, 117, 225-252.	0.4	90
706	Hepatic and Non-Hepatic Hydrothorax in Pediatric Ascites. Clinics and Research in Hepatology and Gastroenterology, 2022, , 101868.	1.5	0
707	Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure. BMC Infectious Diseases, 2022, 22, 23.	2.9	4
708	Analysis of Prognostic Factors for Patients Undergoing Renal Replacement Therapy With Acute Kidney Injury Prior to Living Donor Liver Transplantation. Transplantation Proceedings, 2022, , .	0.6	0
709	Post-Paracentesis Hemoperitoneum From a Bleeding Mesenteric Varix: A Case Report on a Rare Presentation. Cureus, 2022, 14, e21298.	0.5	1
710	Chylous Ascites Due to Hyperthyroidism and Heart Failure. Internal Medicine, 2022, , .	0.7	1
711	Nonâ€selective betaâ€blockers in patients with ascites: TheÂcomplex interplay among the liver, kidney and heart. Liver International, 2022, 42, 749-761.	3.9	18

#	Article	IF	CITATIONS
713	Listerial Spontaneous Bacterial Peritonitis. Cureus, 2022, 14, e22051.	0.5	2
715	Feasibility, Efficacy, and Safety of Percutaneous Muscle Biopsies in Patients With Chronic Liver Disease. Frontiers in Physiology, 2021, 12, 817152.	2.8	1
716	Fontanâ€associated liver disease. Hepatology, 2022, 75, 1300-1321.	7.3	21
717	Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy. Seminars in Liver Disease, 2022, 42, 138-150.	3.6	9
718	Evaluation of the mechanisms of sarcopenia in chronic inflammatory disease: protocol for a prospective cohort study. Skeletal Muscle, 2021, 11, 27.	4.2	5
719	Antibiotics and Liver Cirrhosis: What the Physicians Need to Know. Antibiotics, 2022, 11, 31.	3.7	16
720	Improved Mortality But Increased Economic Burden of Disease in Compensated and Decompensated Cirrhosis. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, .	2.2	1
722	Antibiotic Prophylaxis for Upper Gastrointestinal Bleed in Liver Cirrhosis; Less May Be More. Digestive Diseases and Sciences, 2023, 68, 284-290.	2.3	3
723	Management of liver cirrhosis in patients with hepatocellular carcinoma. Chinese Clinical Oncology, 2013, 2, 34.	1.2	5
724	Diastolic dysfunction is associated with low urinary sodium excretion in patients with decompensated cirrhosis. Annals of Hepatology, 2016, 15, 545-751.	1.5	8
725	Trends and Outcomes of Alcoholic Liver Cirrhosis Hospitalizations in the Last Two Decades: Analysis of the Nationwide Inpatient Sample. Gastroenterology Research, 2022, 15, 91-99.	1.3	2
726	LVP vs TIPS for Refractory Ascites: Where Do We Stand?. Digestive Disease Interventions, 0, 06, .	0.2	0
727	Position statement on the use of albumin in liver cirrhosis. Annals of Hepatology, 2022, 27, 100708.	1.5	7
728	comprehensive review on influence of protein and sodium on liver cirrhosis. International Journal of Health Sciences, 0, , 5470-5475.	0.1	0
729	Overview of Complications in Cirrhosis. Journal of Clinical and Experimental Hepatology, 2022, 12, 1150-1174.	0.9	18
730	Pediatric acute viral hepatitis with atypical variants: Clinical dilemmas and natural history. World Journal of Hepatology, 2022, 14, 945-956.	2.0	0
731	Pediatric acute viral hepatitis with atypical variants: Clinical dilemmas and natural history. World Journal of Hepatology, 2022, 14, 944-955.	2.0	1
732	A Metabolomic Analysis of Cirrhotic Ascites. Molecules, 2022, 27, 3935.	3.8	3

#	Article	IF	CITATIONS
733	Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases. Mayo Clinic Proceedings, 2022, 97, 1380-1395.	3.0	O
734	Clinical, Laboratory and Bacterial Profile of Spontaneous Bacterial Peritonitis in Vietnamese Patients with Liver Cirrhosis. Hepatic Medicine: Evidence and Research, 0, Volume 14, 101-109.	2.5	1
735	Point-of-Care Abdominal Ultrasonography (POCUS) on the Way to the Right and Rapid Diagnosis. Diagnostics, 2022, 12, 2052.	2.6	7
736	MANAGEMENT OF ASCITES IN CIRRHOSIS. Problemy Zdorovʹâ I èkologii, 2012, , 28-35.	0.1	0
737	Human Serum Albumin Infusion in Liver Cirrhosis. , 2022, , 113-125.		0
738	Serous body fluid evaluation using the new automated haematology analyser Mindray BC-6800Plus. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1786-1795.	2.3	1
739	Spontaneous Bacterial Peritonitis in Decompensated Liver Cirrhosis—A Literature Review. Livers, 2022, 2, 214-232.	1.9	7
740	Human stem cells for decompensated cirrhosis in adults. The Cochrane Library, 2022, 2022, .	2.8	0
741	Renal Insufficiency in Patients with Cirrhosis. Clinics in Liver Disease, 2022, , .	2.1	0
742	Use of Human Albumin Administration for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 5928.	2.4	5
744	Diagnostic accuracy of serum ascites albumin gradient (SAAG) in a contemporary unselected medical cohort. Journal of International Medical Research, 2022, 50, 030006052211403.	1.0	1
745	Elevated calprotectin levels are associated with mortality in patients with acute decompensation of liver cirrhosis. World Journal of Hepatology, 0, 14, 1964-1976.	2.0	4
746	Effects of Short-Term Human Albumin Infusion for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis. Journal of Clinical Medicine, 2023, 12, 107.	2.4	2
747	Preoperative Assessment and Optimization of Liver Transplant Patient: Ascites and Hydrothorax., 2023, , 115-126.		1
748	Bacteremia (Sepsis), Hepatorenal Syndrome, and Serum Creatinine Levels Rather than Types or Microbial Patterns Predicted the Short-Term Survival of Cirrhotic Patients Complicated with Spontaneous Bacterial Peritonitis. Diagnostics, 2023, 13, 94.	2.6	1
749	Interferon- $\hat{l}^3$ secreted by recruited Th1 cells in peritoneal cavity inhibits the formation of malignant ascites. Cell Death Discovery, 2023, 9, .	4.7	2
750	Preanalytic Considerations. , 2023, , 1-19.		0
751	Diagnosis and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome. Cleveland Clinic Journal of Medicine, 2023, 90, 209-213.	1.3	2

#	ARTICLE	IF	CITATIONS
752	Human Albumin Infusion for the Management of Liver Cirrhosis and Its Complications: An Overview of Major Findings from Meta-analyses. Advances in Therapy, 2023, 40, 1494-1529.	2.9	4
753	Paracentesis evacuante en pacientes cirr $ ilde{A}^3$ ticos con ascitis a tensi $ ilde{A}^3$ n: revisi $ ilde{A}^3$ n del tema. latreia, 2010, 23, .	0.1	0
754	Urea Transporter Inhibitor 25a Reduces Ascites in Cirrhotic Rats. Biomedicines, 2023, 11, 607.	3.2	1
755	Fontan-associated liver disease: Diagnosis, surveillance, and management. Frontiers in Pediatrics, 0, 11,	1.9	7
756	Primary spontaneous listerial peritonitis. IDCases, 2023, 32, e01748.	0.9	1
758	Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis. American Journal of Health-System Pharmacy, 2023, 80, 806-817.	1.0	1
759	Hepatorenal syndrome: Current concepts and future perspectives. Clinical and Molecular Hepatology, 2023, 29, 891-908.	8.9	3
760	Ascites and Chronic Liver Disease in Children. Indian Journal of Pediatrics, 2024, 91, 270-279.	0.8	2
761	Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders. Antibiotics, 2023, 12, 1068.	3.7	2
762	Use of albumin infusion for cirrhosis-related complications: An international position statement. JHEP Reports, 2023, 5, 100785.	4.9	7
763	Emergency medicine updates: Spontaneous bacterial peritonitis. American Journal of Emergency Medicine, 2023, 70, 84-89.	1.6	0
765	Retrospective Investigation of Factors Affecting Mortality in Spontaneous Bacterial Peritonitis. Euroasian Journal of Hepato-gastroenterology, 2023, 13, 5-9.	0.5	0
766	Renal dysfunction in chronic liver disease: Current concepts, classification, and management. Gastroenterology, Hepatology and Endoscopy Practice, 2021, 1, 2.	0.2	1
767	Molecular mechanisms of alcohol's effects on the human body: A review and update. Journal of Biochemical and Molecular Toxicology, 0, , .	3.0	1
768	Effect of early administration of tolvaptan on pleural effusion post-hepatectomy. Langenbeck's Archives of Surgery, 2023, 408, .	1.9	0
769	CON: Ascitic fluid cell count should not be routinely sent with every therapeutic paracentesis to assess for spontaneous bacterial peritonitis. Clinical Liver Disease, 2023, 22, 143-145.	2.1	0
770	Efficacy and safety of postoperative preemptive use of tolvaptan for patients with cirrhosis undergoing hepatectomy for hepatocellular carcinoma. Langenbeck's Archives of Surgery, 2023, 408, .	1.9	0
771	The experiences of people with liver disease of palliative and endâ€ofâ€ife care in the United Kingdom—A systematic literature review and metasynthesis. Health Expectations, 2024, 27, .	2.6	1

#	Article	IF	CITATIONS
772	What Are the Causes and Complications of Chronic Liver Disease and What Is the Evidence for Palliative Care Delivery to Those Affected by It?., 2023,, 357-370.		0
774	Differential diagnosis of ascites: etiologies, ascitic fluid analysis, diagnostic algorithm. Clinical Chemistry and Laboratory Medicine, 2023, .	2.3	O
775	Zonulin is not Useful for the Diagnosis of Intestinal Permeability in Cirrhotic. Journal of Ankara University Faculty of Medicine, 2023, 76, 328-332.	0.1	0
776	Optimizing Outcomes in Patients with Ascites Complicating Cirrhosis—Maximizing the Hour of Power. Digestive Diseases and Sciences, 2024, 69, 1080-1082.	2.3	0
777	Effectiveness of antibiotic prophylaxis for acute esophageal variceal bleeding in patients with band ligation: A large observational study. World Journal of Gastroenterology, 0, 30, 238-251.	3.3	0
778	Ascitic Fluid Lactate Level as a Predictor of Mortality in Cirrhotic Patients Having Spontaneous Bacterial Peritonitis (SBP). Cureus, 2024, , .	0.5	O
779	Biological Fluids. , 2023, , 475-488.		0
780	Diagnosis and Management of Hepatic Hydrothorax. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2024, 83, 45-53.	0.4	O
781	SARS-CoV-2 Infection Is an Independent Risk Factor for Decompensation in Cirrhosis Patients. Diseases (Basel, Switzerland), 2024, 12, 46.	2.5	0
782	Aetiology and diagnostic utility of serum ascites albumin gradient in children with ascites. Digestive and Liver Disease, 2024, , .	0.9	0
783	Information Needs of Patients with Cirrhosis of the Liver and Quality of Life. Revista Colombiana De Gastroenterologia, 2024, 39, 14-28.	0.2	0